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ABSTRACT 
 
CDK2/cyclin A and CDK4/cyclin D1 are proven targets for cancer drug discovery.  The 
development of novel CDK inhibitors, with high selectivity, are being investigated by 
targeting the cyclin binding groove (CBG) located on the cyclin, the regulatory subunit of 
CDK.  The CBG is a shallow area that is involved in signaling and the inhibition of cell 
cycle CDKs via endogenous tumor suppressors.  Currently, non-peptidic inhibitors are 
being developed based on the recognition amino acid sequence, HAKRRLIF, of the C-
terminal peptide sequence of the CDK inhibitor p21
WAF1
.  Computational design and the 
utilization of non-natural amino acids are being proposed in identifing small molecules to 
replace the C-terminal amino acids (RLIF) via the REPLACE methodology.  Such small 
molecules, known as capping groups, have significant potential for converting the 
octamer into a more drug-like molecule.  The REPLACE methodology has been applied 
and used to identify novel Ccaps to replace RLIF and these Ccaps have IC50 values in the 
40-100 μM range against the cell cycle CDK/cyclin complexes of interest.  Fragment 
ligated inhibitory peptides (FLIPs) have been synthesized, coupled with a potent small 
molecule N-terminal capping group (Ncap), and their binding affinities have been tested 
using a Fluorescence Polarization (FP) assay.  The results reported here enhance the 
development of a selective, drug-like, cell permeable small molecule CDK cyclin groove 
inhibitors by generating promising Ccaps and by identifying a novel approach to the 
designing of potential partial ligand alternatives.  Further, these results bring us closer to 
achieving the ultimate goal of developing a novel class of cancer therapeutics based on 
v 
cell cycle inhibition through cyclin dependent kinases. 
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CHAPTER 1 
INTRODUCTION
 
Cyclin dependent kinases (CDKs) play a major role in many cellular processes including 
the mammalian cell cycle.  CDKs are heterodimeric structures that contain two subunits, 
the catalytic kinase and the regulatory cyclin.  This complex is responsible for the 
phosphorylation of various substrates to tightly control cell proliferation.  Other proteins 
also regulate the cell cycle such as CDK inhibitors and tumor suppressor proteins.  These 
proteins, among others, work together to promote or suppress DNA replication and in a 
perfect world this is done without disruptions or damage.  However, through genetic or 
environmental disturbance, many aspects of the cell cycle can be deregulated or disrupted 
by mutation, overexpression, or amplification.  Currently, several approaches are being 
studied to identify potential CDK inhibitors to help restore regulation in cells with 
uncontrolled proliferation.  These include, but are not limited to, targeting the ATP 
binding pocket on the kinase and the substrate recruitment site located on the cyclin.  In 
this chapter, the details of the cell cycle, altered functions of endogenous proteins and the 
current therapeutic approaches will be discussed.  
1.1 ROLE OF CDK/CYCLIN COMPLEXES IN THE CELL CYCLE 
The mammalian cell cycle is the process in which cells replicate and divide to form two 
daughter cells from a single parental cell.  There are four consecutive phases of the cell 
cycle that must occur in order for the cell to properly divide.  These phases are Gap 1 
2 
(G1), Synthesis (S), Gap 2 (G2), and Mitosis (M).  Additionally, there is a resting phase 
known as Gap 0 (G0) which is considered to be a sub-phase of G1 and contains non-
proliferating cells
1
.  During G1 phase the cell prepares for the entry into S phase by 
expressing proteins required for S phase
1
.  During S phase, DNA is replicated, in G2 
phase the cell prepares for the entry into M phase, and during M phase the cell undergoes 
cellular division
1
.   
Each phase of the cell cycle is tightly controlled by specific CDKs.  This protein 
family contains more than 20 members and individual isoforms can be involved in 
distinct cellular functions including both cell cycle progression and/or transcription.  
During the cell cycle, CDKs complex with a regulatory cyclin and phosphorylate various 
substrates to promote cell proliferation.  During G1, CDK4 and CDK6 complex with the 
D-type cyclins and these heterodimers are essential for progression through this phase
1
.  
Late in G1, CDK2 binds to cyclin E to regulate the transition from G1 to S phase.  In G2, 
CDK1 complexes with cyclin A to promote entry into M phase and in M phase, CDK1 
binds to cyclin B to help promote cellular division
1
 (Figure 1.1 and Table 1.1).  CDK 
protein levels remain constant throughout the cell cycle unlike the cyclins whose levels 
oscillate to activate specific CDKs and to tightly control each phase of cell proliferation.  
Unlike most others, the D-type cyclin (D1, D2, and D3) levels are maintained throughout 
the cell cycle and their activity is regulated by growth factors/mitogenic stimulation
1-2
.   
During transcription, two other CDKs (7 and 9) are active
3
.  These CDKs promote 
the initiation and elongation of nascent RNA transcripts by phosphorylating the carboxy-
terminal domain (CTD) of RNA polymerase II
2a
.  CDK7 and 9 are subunits of TFIIH and 
p-TEFb, respectively, in which they activate RNA polymerase II
4
.  TFIIH is critical for 
3 
stabilizing of the elongation factors and p-TEFb promotes productive elongation
5
. 
 
TABLE 1.1. SUMMARY OF CDK/CYCLIN COMPLEXES DURING EACH PHASE OF THE CELL CYCLE.   
 
CDK Cyclin Cell Cycle Phase 
4 D G1 
6 D G1 
2 E Late G1 into S 
2 A S 
1 A G2 into M  
1 B M 
 
The G1/S phase transition is a critical point in the cell cycle.  Cells either commit to 
or abandon cell cycle progression.  This process is complex and the retinoblastoma 
protein (pRb) is at the center of all the action.  pRb is a tumor suppressor protein whose 
primary function is to tightly regulate cell proliferation during the G1 phase
6
.  When 
FIGURE 1.1. STAGES OF THE CELL CYCLE  The four stages of the mammalian cell cycle consist of Gap 1 
(G1), Synthesis (S), Gap 2 (G2), and Mitosis (M) phases.  G0 is a sub-phase of G1 and contains non-
proliferating cells.  During G1 phase, CDK4/cyclin D and CDK6/cyclin D complexes are active.  During S, 
G2, and M phases, CDK2/cyclin E and CDK2/cyclin A, CDK1/cyclin A, and CDK1/cyclin B are active, 
respectively (Vermeulen, et al. 2003). [Figure reproduced with permission from John Wiley and Sons.] 
4 
hypophosphorylated, pRb is able to interact with a transcription factor, E2F-1, and also 
with histone deacetylase-1 (HDAC1) to inhibit progression through the cell cycle
2a
.  
When pRb is bound to E2F-1, the transcription of genes necessary for entry into S phase 
is inhibited.  When pRb is hyperphosphorylated by CDK4/6-cyclin D complexes late in 
G1, the inhibitory effects of pRb are abolished and transcription is promoted.  
Phosphorylation of pRb causes a disruption of the trimeric complex of pRb, HDAC1 and 
E2F-1
1-2
.  E2F-1 is therefore released, able to bind with its heterodimeric partner, DP-1, 
and together they direct the transcription of genes required for S phase. The cell can then 
pass through what is known as the restriction point and from this point the cell is 
committed to a single round of replication
2a, 7
.  As a result of E2F-1 promoting 
transcription, cyclin E is expressed and is able to complex with CDK2 to maintain pRb in 
a hyperphosphorylated state for the remainder of the cell cycle
1, 2b
.   
 During S phase of normal cells, the DNA of a cell must only replicate once and 
prior to the completion of this replication, E2F-1 activity must be downregulated to avoid 
potential apoptosis.  CDK2/cyclin A phosphorylation of E2F-1 when bound to DNA is a 
key event in the timely neutralization of E2F-1 activity
2a
.  Phosphorylation of E2F-1 
causes it to be released from the DNA and is therefore no longer able to function as a 
transcription factor
2a
.  The cell is then able to complete S phase and enter G2 where it 
prepares for entry into and progression through mitosis.   
There are four stages of mitosis (prophase, metaphase, anaphase, and telophase) 
that result in the division of a single cell into two daughter cells
1
.  Prophase is when the 
chromosomes begin to condense inside the nucleus and the duplicated centrosomes 
separate to form the poles of the mitotic spindle
7
.  A stage prior to metaphase, known as 
5 
prometaphase, is when the nuclear envelope breaks down and the chromosomes begin to 
attach to the mitotic spindles.  Metaphase involves the completion of this attachment and 
alignment of the chromosomes in the center of the cell
7
.  To aid in the 
metaphase/anaphase transition, CDK1/cyclin A and B phosphorylate the anaphase 
promoting complex (APC)
7
.  In turn the APC ubiquitinates cyclins A and B, marking 
them for degradation, resulting in a repression of CDK activity which is critical for the 
cell to exit mitosis and for the reentry into G1
7
.  Once in anaphase, the cell begins to exit 
mitosis and the two sets of chromosomes split and approach the mitotic spindle poles, 
meanwhile the nuclear envelope begins to reform as a precursor to telophase
7
.  In 
telophase, the cell begins to divide in two and the final separation into daughter cells is 
termed cytokinesis
7
.   
1.2 ENDOGENOUS CDK/CYCLIN INHIBITORS 
Along with the CDK/cyclin complexes, there are other regulators that are required for the 
cell to successfully progress through the cell cycle.  The regulation of cell proliferation is 
aided by inhibitory proteins which bind to CDKs (CDKIs).  There are two distinct 
families of CDKIs, INK4 and Cip/Kip
1
.  The INK4 family preferentially inactivates 
CDK4/6 and consists of at least four members (p15
INK4b
, p16
INK4a
, p18
INK4c
, and 
p19
INK4d
)
1
.  These proteins bind to monomeric CDK to prevent their association with the 
D-type cyclins
1
.  The activities of the INK4 family results in the inhibition of the cell 
cycle in G1 by disrupting the ability of CDK4/6 to phosphorylate pRb
2b
.  Without pRb 
phosphorylation, E2F-1 activity is inhibited and the cell never enters S phase
2b
.  The 
mechanism of action in which INK4 inhibitors bind and inhibit the CDK protein is 
through binding near the adenosine triphosphate (ATP) binding site which alters its 
6 
conformation and allosterically prevents ATP from binding
2b
.   
 The Cip/Kip family inactivates the CDK/cyclin complexes of CDK1, CDK2, 
CDK4, and CDK6.  These inhibitory proteins include p21
WAF1
, p21
Cip1
, p27
Cip2
, and 
p57
Kip2
 
1
.  Each of these proteins contains a conserved sequence known as the cyclin 
binding motif (CBM)
2b
.  These proteins interact with the cyclin through this motif via 
protein-protein interactions (PPI) at a shallow hydrophobic region on the cyclin known as 
the cyclin binding groove (CBG).  Other proteins (i.e. E2F-1, pRb, etc) also contain the 
CBM and interact with the CBG in a similar manner prior to their phosphorylation by the 
CDK/cyclin complexes.  These interactions will be discussed in detail in Section 1.5.  
The expression of p21
WAF1
 is under transcriptional control of p53, a tumor suppressor 
protein
1
.  The levels of p53 are generally kept low with in the cell however, when there is 
DNA damage (replication errors, external damaging agents such as X-rays or UV light) 
p53 levels accumulate enough for the expression of p21
WAF1
 to occur, resulting in cell 
cycle arrest
8
.   
 To bring all of this into perspective, Figure 1.2 illustrates the stages and regulation 
of the cell cycle along with a few of the numerous proteins involved.  In brief, starting at 
G1 (far bottom left) we have an INK4 protein bound to CDK4/6, inhibiting the 
interaction with cyclin D.  Upon mitogenic stimuli the transcription of cyclin D occurs.  
When the INK4 protein is removed from CDK4/6, the kinases are able to complex with 
cyclin D and upon phosphorylation by a CDK activating kinase (CAK; CDK7/cyclin H – 
activates many CDK/cyclin complexes), the CDK4/6/cyclin D complexes become fully 
activated.  pRB is phosphorylated by CDK4/6/cyclin D complexes releasing E2F and 
promoting the transcription of various genes necessary for S phase (i.e. cyclin E).  CDK2 
7 
associates with cyclin E to further phosphorylate pRb.  CDK2 association with cyclin A 
is required for DNA replication and this complex can be blocked by the Cip/Kip family 
of CDKIs.  Late in S phase, CDK1 binds to cyclins A and B, promoting APC (not shown 
in the figure) to ubiquitinate cyclins A and B for their necessary degradation and the 
progression of the cell cycle.  Vermeulen, et al. (2003) explains this figure more in 
depth
1
.  The CDK/cyclin complexes and other protein activities can be inhibited by 
Cip/Kip CDKIs by various pathways 
2b
.   
 
Also controlled by CDKs are checkpoints throughout the cell cycle.  These 
checkpoints aid in the regulation of proliferation, ensure that the cell is in its optimum 
state prior to the transition from one phase to the next, and are sensitive to problems 
within DNA replication or within the cellular environment
7
.  The first type of checkpoint 
FIGURE 1.2. OVERVIEW OF SOME ESSENTIAL PROTEINS INVOLVED IN CELL CYCLE REGULATION.   
: phosphorylated site, : activation, and ׀—: inhibition (Vermeulen, et al. 2003). [Figure reproduced 
with permission from John Wiley and Sons.] 
8 
is the restriction point late in G1.  This checkpoint is sensitive to the physiological state 
of the cell and its environment and with inappropriate mitogenic signaling, the cell will 
not transition into S phase
7
.  This restriction point is considered the “point of no return” 
for the cell cycle
1
.  It is at this point that the cell either commits to or abandons cell cycle 
progression.  The second type of checkpoint is the DNA damage checkpoint.  G1, S, and 
G2 phases each have this checkpoint which has the ability to block cell proliferation
7
.  If 
DNA damage is detected, the checkpoint will arrest the cell cycle to allow time for DNA 
repair
1
.  If the damage is too advanced the cell will undergo apoptosis
7
.   
The third type of checkpoint is the DNA replication checkpoint.  This checkpoint 
has the ability to detect unreplicated DNA or malfunctioned replication machinery
7
.  If 
such problems arise, this checkpoint is able to aid in the stabilization of the replication 
machinery to promote repair or to further DNA replication
7
.  The last type of checkpoint 
is the spindle assembly checkpoint.  This checkpoint ensures that all chromosomes have 
properly attached to the mitotic spindle prior to chromosome segregation
7
.  If improper 
attachment to the spindle is detected, the cell will arrest in mitosis
1
.   
1.3 ALTERED FUNCTIONS OF CDK/CYCLINS AND ENDOGENOUS INHIBITORS IN 
TRANSFORMED CELLS 
 
CDKs are key players in regulating many important cellular functions (cell cycle control, 
cell signaling, apoptosis, gene transcription, etc.) and their deregulation is associated with 
numerous diseases, in particular cancer
9
.  One of the most common deregulation events 
during the cell cycle involves the CDK4/6-cyclin D-INK4-pRb pathway.  This pathway is 
ubiquitously disrupted in mammalian cancers
2a, 9b
.  The functional inactivation of the 
tumor suppressor gene, pRb causes dysfunction of proteins that endogenously inhibit the 
9 
proliferation
1
.  Deregulation is most often seen in the G1/S phase CDKs (CDK2/4/6) 
which occurs by the mutation of CDKIs (p16
INK4a
, p21
WAF1
, pRb etc.).  These mutations 
provide the means for transformed cells to override the G1 checkpoint resulting in 
uncontrolled cell proliferation
3, 10
.   
The CDKI p16 gene has been found to be altered in numerous tumor types and 
inactivated by a number of mechanisms (deletion, point mutation and hypermethylation)
1-
2
.  With altered p16, cells lack the ability to inhibit CDK4/6-cyclin D resulting in pRb 
being hyperphosphorylated and unable to sequester E2F-1, thus promoting uncontrolled 
cell proliferation
1, 11
.  This inappropriate entry into S phase and overactivation of E2F-1 
should induce apoptosis
11
.  Altered p16 has been noted in glioma, mesothelioma, 
pancreatic, and many other cancer types
1
.   
The CDK4 gene has been found to be amplified and CDK4 protein overexpression 
has been noted in multiple cell lines, particularly in breast cancer
1,
 
12
.  A study conducted 
on CDK4 null mice determined that the animals were resistant to mammary carcinomas, 
the continual presence of CDK4 and cyclin D1 was critical in retaining tumor cell 
proliferation, and the catalytic function of CDK4/cyclin D1 complex is mandatory to 
sustain the tumorigenic potential of breast cancers cells
12
.  Mutant cyclin D1 is able to 
bind to the appropriate CDKs and to the CDKIs p21
Cip1
 and p27
Kip1 
however this mutated 
cyclin lacks the ability to activate the kinase
12
.   
Cyclin D1 is the most ubiquitously expressed cyclin and is present in many cell 
types and tissues
9b
.  Its gene amplification has been observed in bladder, lung, colon, and 
many other malignant cancers and cyclin D1 is known to be a critical regulator of breast 
cancer
1-2
.  Cyclin D1 upregulation is often associated with the loss of p16 function and 
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results in increased levels of CDK4 available to complex with D-type cyclins and 
endogenous CDKIs
2a
.  CDK4/6-cyclin D1 complexes promote the activation of 
CDK2/cyclin E and the phosphorylation of pRb
2a
.  The increased activity of CDK2/cyclin 
E, as a result of the CDK4/6-cyclin D-INK4-pRb pathway being deregulated, further 
causing inappropriate levels of E2F activity, leading to uncontrolled cell proliferation.  
CDK 1 and 2 have been noted to be overexpressed in a subset of colon adenomas, cyclin 
E is amplified and/or overexpression in breast, colon, and many other cancers, and both 
cyclin A and E have been found to be overexpressed in lung carcinoma
1
.   
1.4 ATP COMPETITIVE CDK INHIBITORS 
There are many approaches to the design of kinase inhibitors.  These include blocking of 
the Adenosine Tri-phosphate (ATP) binding pocket, blocking the substrate recruitment 
site, and stabilizing kinases in their inactive conformations
13
.  This section focuses on 
kinase inhibitors that preferentially block the ATP binding pocket.  This pocket is well 
defined and the generation of small molecules inhibitors to block this hydrophobic pocket 
has been studied for many years
13c
.  The ATP binding pocket is composed of five main 
sites, (1) central purine binding site, (2) solvent accessible surface, (3) ribose binding site, 
(4) phosphate binding region, and (5) hinge region
13a
.  Each of these sites are important 
for the binding affinity of ATP, (which is involved in many intermolecular interactions 
including van der Waals, hydrophobic and hydrogen bonding) and are used as guides for 
the structure based design of inhibitors
13a, 13c
.   
CDKs and other proteins have been determined to be critical regulators of the 
eukaryotic cell cycle
13b
, as discussed in Section 1.1.  Gain-of-function and/or loss-of-
function of such proteins during the cell cycle (i.e. cyclins, endogenous CDK inhibitors, 
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and other substrates) cause a snowball effect on the regulatory events of the CDKs 
leading to the transformation of cells
13b
.  CDK4/6 have been determined to be frequently 
amplified or overexpressed in many tumor types and their inhibition would block cell 
proliferation and avert the transcription of genes necessary for cell cycle progression
13b
.  
Also, it has been observed that the absence of CDK2/cyclin E complex in both 
transformed and untransformed cells does not affect cell cycle proliferation
14
.  This raises 
the concern that specific targeting of CDKs may not be of best interest for cancer 
therapeutics, due to redundancies in kinase activity
14
.  There are many kinase inhibitors 
with single and/or multiple targets in the cell cycle and such targets include cell cycle 
CDKs, transcriptional CDKs, or both
15
.  An alternative strategy that does not target the 
catalytic domain would evade the problems of redundancy in kinase activity. 
 PD0332991 (Palbociclib) has recently been approved by the Food and Drug 
Administration (FDA) as a “Breakthrough Therapy”16.  Breakthrough therapy allows a 
drug to be used as treatment while the remainder clinical trials are conducted
16
.  
CDK4/cyclin D1 has been proven to be disrupted in many tumor types by overexpression 
and/or amplification and blocking the ability of CDK4/cyclin D1 to phosphorylate 
substrates necessary for cell cycle progression, is a viable approach to treating cancer
15, 
17
.  PD0332991 is highly selective for CDK4/6 with IC50 values of 11 nM and 15 nM, 
respectively, and exclusively induces G1 arrest
17-18
.  When tested against a panel of 
serine, threonine, and tyrosine kinases, PD0332991 (Figure 1.3) showed very little to no 
activity against kinases other than CDK4/6
18
.   
In retinoblastoma (Rb)-positive cancer cells, it was observed that with treatment of 
PD0332991 (0.011 µmol/L) there was an induction of G1 arrest, a reduction in tumor 
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growth, and in human xenograft models there was tumor regression
15, 19
.  When 
PD0332991 was tested against Rb-negative cancer cells there was no activity
15
, 
concluding that PD0332991 has the ability to halt cancer cell growth in patients with Rb-
positive cancers
17, 20
.  A study was conducted to determine if drug resistance would occur 
with continued use of PD0332991.  Colo-205 human colon carcinoma tumor xenografts 
in mice were negative for resistance after treatment for 14 days with PD0332991 with 
doses of 75-150 mg/kg and tumor regression was observed in some tumors at a dose of 
37.5 mg/kg
18
.  In primary bone marrow myeloma cells, G1 arrest was potently induced 
with doses as low as 0.3 µM and with higher doses (greater than 5 µmol/L) apoptosis was 
induced
21
.   
 
When PD0332991 was used in combination with dexamethasone, apoptosis was 
enhanced with treatment for 48 hours of 0.01µM of drug in bone marrow myeloma 
cells
21
.  In disseminated human myeloma xenografts, tumor growth was completely 
inhibited
21
.  More recently, when used in combination with Femara (Letrozole), an anti-
hormonal agent, there was an increase in progression-free survival of about 3.5 fold
20
.  A 
Phase 3 clinical trial is currently recruiting for first-line treatment of postmenopausal 
FIGURE 1.3. CHEMICAL STRUCTURE OF PD0332991.  Chemical structure of 6-acetyl-8-cyclopentyl-5-
methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one. 
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women with ER-positive/HER2-negative advanced breast cancer.  Treatment will be 
conducted with PD0332991 in combination with Letrozole and Letrozole alone.   
There are multiple CDK inhibitors targeting the G1 and S phases that are currently 
in clinical trials, however, PD0332991 is the only orally bioavailable drug that has high 
specificity for CDK4/6 kinases
17
.  During Phase 1 and 2, the most common dose-limiting 
toxicities were myelosuppression, nausea, vomiting, diarrhea, and fatigue
17
.  Neither 
vascular thrombotic nor neurological adverse events were observed with PD0332991 
treatment as has been observed with other CDK inhibitors in clinical trials
17
.   
 A second CDK inhibitor that targets the ATP binding pocket is Flavopiridol 
(alvocidib, HMR1275; Figure 1.4).  This compound is active against multiple kinases but 
is known to be most potent against the transcriptional CDK, CDK9, relative to other 
kinases
15
.   
 
Early studies showed that flavopiridol potently inhibited CDK2 and CDK4 with 
IC50 values between 50-120 nM
22
.  In MCF-7 (p53 and Rb proficient) and MDA-MB-468 
(p53 and Rb deficient) cells, G1 arrest was induced, proving that the action of 
flavopiridol is independent of p53 and Rb
22
.  MCF-7 cells showed a significant loss in 
cyclin D levels without altering the levels of cyclin A, cyclin E, CDK2, or CDK4.  These 
FIGURE 1.4. CHEMICAL STRUCTURE OF FLAVOPIRIDOL.  Chemical structure of 2-(2-chlorophenyl)-5,7-
dihydroxy-8-((3R,4S)-3-hydroxy-1-methylpiperidin-4-yl)-4H-chromen-4-one.   
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results led to the conclusion that flavopiridol inhibits CDK2/4 kinase activity resulting in 
G1 arrest
22
.  However, studies conducted in head and neck squamous cell carcinoma 
(HNSCC) cell lines showed that flavopiridol caused a significant decrease in CDK1/2 
activity with IC50 values between 43-83 nM
23
.   
Fischer and Gianella-Borradori (2003) summarizes the potency and selectivity 
profile of flavopiridol.  They summarized that against the transcriptional kinase 
CDK9/cyclin T1, flavopiridol is most potent with an IC50 value of 0.006-0.01 µM.  In 
2010, studies show that flavopiridol treatment resulted in the inhibition of the C-terminal 
domain of RNA-polymerase-II causing an inhibition in transcription resulting in 
apoptosis
24
.  When tested against CDK1/cyclin B and CDK4/cyclin D1 flavopiridol 
showed IC50 values of  <0.1 µM, and against CDK2/cyclin A, CDK2/cyclin E, 
CDK7/cyclin H, and other kinases (epidermal growth factor receptor, protein kinase C, 
etc.) flavopiridol has IC50 values of ≥0.1 µM
25
.    
A study was conducted on a panel of human tumor xenografts
26
.  Flavopiridol was 
proven to be highly potent against prostate and less potent against melanoma, breast, 
lung, and ovarian cancers
26
.  In nude mice containing prostate cancer xenografts 
(PRXF1369), flavopiridol showed a maximum tolerated dose (MTD) of 10 mg/kg/day 
and a tumor growth delay of 30 days
26
.  In human promyelocytic leukemia (HL-60) 
xenografts, animals experienced complete regression and remained disease free for 
several months.  In human B-cell follicular lymphoma (SUDHL-4) xeongrafts, animals 
underwent major or complete regression and were disease free for more than two months 
at 7.5 mg/kg concentrations
27
.   
 Flavopiridol was the first CDK inhibitor to enter clinical trials.  As a single-agent, 
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in Phase 2 clinica trials, flavopiridol induced pro-inflammatory syndrome at doses of 50 
mg/m
2
 in patients with advanced cancers
28
 and showed to have no effect on advanced 
colorectal and non-small cell lung cancer as well as several other cancer as first line 
treatment
29
.  Flavopiridol does have a minimal response as a second-line therapy in 
endometrial adenocarcinoma and advanced renal cell carcinoma
30
.  When flavopiridol 
was used in combination therapy, significant antitumor activity was observed.  In the 
administration of flavopiridol after gemcitabine there was a 10-15 fold increase of 
apoptosis in pancreatic, gastric, and colon cancer cell lines
31
.   
 A third ATP-competitive inhibitor is JNJ-7706621(Figure 1.5).  This compound is 
a multi-targeted/pan kinase inhibitor that targets CDKs and Aurora kinases
32
.  As stated 
previously, CDKs play a central role in the cell cycle and their activity is dependent upon 
the regulatory subunit, cyclin.  Aurora kinases play an important role during mitosis, in 
regulating chromosomal movement and organization
33
.   
 
JNJ-7706621 is a 1,2,4-triazole-3,5-diamine derivative and is moderately potent 
inhibitor of CDK1 and 2 (moderately potent against CDK4) and Aurora kinases A and 
B
33-34
.  When tested against a large number of other protein kinases JNJ-7706621 had 
little to no activity
15
.  A CDK1 kinase assay was conducted, in the presence of 5 µM ATP 
and JNJ-7706621 showed to have an IC50 value of 17.12±1.03 µM
33
.  Against PC3 
FIGURE 1.5. STRUCTURE OF JNJ-7706621.  The chemical structure of 1-(2’,6’-difluorobenzoyl)-5-amino-
3-(4’aminosulfonylanilino)-1,2,5-triazole.   
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prostate cancer cells and HCT-116 colon cancer cells, JNJ-7706621 showed potent 
inhibition with IC50 values of 0.112±0.012 µM and 0.189±0.042 µM, respectively.  It was 
observed that JNJ-7706621 resulted in a delay in cell cycle progression in G1 and cell 
cycle arrest was observed at the G2/ M phases in human cancer cells
33-34
.  It was 
determined that JNJ-7706621 is a potent antiproliferative agent against numerous cancer 
cell types, irrespective of p53, retinoblastoma (Rb) or P-glycoprotein levels
33
.  However, 
JNJ-7706621 has poor solubility and studies have been conducted on potentially utilizing 
nanoparticles as non-toxic vehicles for its delivery
34
.   
1.5 NON-ATP COMPETITIVE CDK INHIBITORS 
A different approach to the development of CDK inhibitors is to target alternative sites 
other than the ATP binding site
35
.  Targeting the ATP binding site has proven to be 
beneficial in the development of cancer therapeutics.  It is well known that the ATP 
binding pocket is conserved across all kinases and present in many proteins that are 
involved in numerous cellular functions.  There are risks in potentially inhibiting 
transcriptional CDKs by causing effects on normal cells which may account for the 
toxicities observed with clinically evaluated CDK inhibitors
3
.  The ultimate goal in novel 
chemotherapeutic development is to identify a target that is unique to a specific cancer 
cell or when inhibited will allow the cancer cell to be sensitized to cell death.  It has been 
established that many biological processes are regulated through protein-protein 
interactions (PPI) and theoretically, if identifiable, PPIs could be blocked specific 
proteins or pathways would be inhibited.   
 During the cell cycle the cyclin binding groove (CBG) of the cyclin subunit is 
involved in the recruitment of various substrates for phosphorylation
35
.  The CBG 
17 
recognizes a short peptide sequence known as the cyclin binding motif (CBM).  Figure 
1.6 illustrates a CDK2/cyclin A heterodimer.  This motif is conserved in many cell cycle 
substrates and inhibitory proteins and has been identified to interact specifically with the 
CBG through PPIs.  Substrates involved in the cell cycle are recognized by the CBG 
through the CBM, are recruited into close proximity of the groove, and are 
phosphorylated by the active CDK/cyclin complex.   
 
 Often times, the negative regulators of the cell cycle (p21, p27, etc.) are inactivated 
resulting in upregulation of CDK activity.  This can cause an override of the phase 
checkpoints (described in Section 1.2) and may lead to uncontrolled cell proliferation and 
to the transformation of cells.  Cellular response through the inhibition of the CBG is 
greater in transformed cells because E2F-1 is frequently deregulated in such cells and has 
been reported to induce apoptosis in combination with CDK2/cyclin A inhibition
36
.  
Transformed cells depend on CDK2/cyclin A to decrease the activity of E2F-1 to avoid 
the induction of apoptosis in late S phase
10b
.   
FIGURE 1.6. CDK2/CYCLIN A/P27 TRIMERIC COMPLEX.  Illustration of a CDK2/cyclin A complex with 
the ATP binding site located on the kinase (red) and the cyclin groove on the cyclin (blue).  p27 (yellow) 
is shown interacting with both the ATP binding site and the cyclin groove.    
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Due to the CBM being conserved across the Cip/Kip family members (Section 1.2), 
selective inhibitors can be designed to block the CBG and inhibit the activity of the 
CDK/cyclin complexes resulting in the induction of apoptosis in transformed cells.  
Peptides composed of naturally occurring amino acids are useful for lead compounds in 
discovering new drug therapies but generally speaking are limited as therapeutics by their 
undesirable pharmacokinetic profiles.  These are caused by their poor permeability (blood 
brain barrier, cell membrane, etc.) and lack of metabolic stability including protease-
mediated degradation
37
.  Currently, HAKRRLIF, based on the C-terminal domain of 
p21
WAF1
, is being used in structure based design to develop non-peptidic inhibitors for 
CDK2/cyclin A and CDK4/cyclin D1 references.   
Previously mentioned in Section 1.4, selective inhibition of kinases may not be of 
best interest due to redundancies in the kinase activity.  An approach, targeting the CBG, 
reduces the possibility of such problems because it is the protein kinase that is known to 
be redundant
14
 not the cyclin.  Cyclin groove inhibitory compounds should be selective 
due to cyclins A, D, and E being the only cyclins containing a functional binding groove 
and thus are potential targets for non-ATP competitive CDK inhibitors
38
.  CDK2/cyclin 
A and CDK4/cyclin D1 are validated anticancer drug targets, targeting the CBG of these 
kinases provides selectivity, and the kinases involved in other cellular processes will not 
be affected
38
.  However, it has been determined that potent CDK2/cyclin A inhibitors 
generally are significantly less effective against CDK4/cyclin D1
38
.  Due to these 
differences Liu, et al. (2010), set out to determine which structural variants between 
cyclin A and D1 might affect the potency of CDK inhibitors.  In terms of the CBG, there 
are three major sites of the hydrophobic cleft that are involved the binding of 
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HAKRRLIF: 1) a primary hydrophobic pocket that interacts with Leu6 and Phe8 (the 6
th
 
and 8
th
 amino acids of HAKRRLIF)
38
 2) a secondary hydrophobic pocket that interacts 
with Ala2 and 3) an acidic region, located between the two lipophilic pockets, that forms 
ionic contacts with the basic amino acids, Arg4 and Arg5
38
.   
 To determine the differences in the CBG of cyclin A and D1, their crystal 
structures were overlaid and the following variants were determined (Figure 1.7).  On the 
left-hand side of Figure 1.7, the black chemical structure represents Leu6 and Phe8 of 
HAKRRLIF.  The residues of the primary hydrophobic pocket of the CBG are L214 
(Leu) and V60 (Val) for cyclin A and D1, respectively.  The residues E220 (Gln) and 
D216 (Asp) make up the acidic region for cyclin D1 and E66 and T62 (Thr) for cyclin A.  
As for the secondary hydrophobic pocket, the amino acids W217 (Trp) and W63 
constitute this pocket for cyclin A and D1, respectively.  The other residues shown are 
considered to be non-peptide contacting residues.  These residues are structurally 
different between Cyclin A and D1.  I281 (Ile) of cyclin A is exchanged for Y127 (Tyr) 
in cyclin D1 (also seen in the ribbon representation right-hand side of Figure 1.7) within 
residue region of 116-136 and these differences lead to altered conformations of the CBG 
in cyclin D1 compared to cyclin A
38
.  Cyclin D1 is able to accommodate larger functional 
groups in the primary hydrophobic pocket because this region is larger and contains an 
extension, compared to cyclin A
38
.  Figure 1.8 illustrates these structural variants using 
the solvent accessible surface of each cyclin.  As a whole, it was determined that cyclin 
D1 contains a narrower secondary pocket, a shallower yet larger primary hydrophobic, 
and a less acidic region at Asp283 compared to cyclin A
38
.  The variation in the CBG 
between cyclin A and D1 is significant enough to cause differences in binding affinities 
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between CDK inhibitors discussed below.  
 
Non-peptidic inhibitors are being developed by the REPLACE (REplacement with 
Partial Ligand Alternatives through Computational Enrichment) strategy (Figure 1.9).  
This strategy is an effective way to iteratively convert peptidic analogs involved in PPIs 
to non-peptidic, drug-like small molecules
3, 10b
.  Computational chemistry is utilized to 
identify partial ligand alternatives (PLAs) by docking small molecule fragments into the 
cyclin groove and evaluating their interactions compared to that of the native ligand
35
.  In 
brief, REPLACE is carried out by the truncation of the N-terminal amino acids of the 
lead peptide and computationally designed PLAs are coupled through solid-phase 
synthesis.  These FLIP compounds are then tested in a competitive binding assay and 
those with substantial activities against CDK/cyclin complexes of interest are further 
optimized by the truncation and replacement of the central and C-terminal amino acids 
FIGURE 1.7. COMPARING THE CYCLIN BINDING GROOVE OF CYCLIN A AND CYCLIN D1. (Left) Overlay 
crystal structure of cyclin A2 (PDB 10KV; Carbon atoms green) and cyclin D1 (PDB 2W96; Carbon atoms 
orange).  (Right) Overlay of the ribbon representation of both cyclin A2 (Red) and cyclin D1 (yellow).  An 
inhibitory peptide (blue) is shown interacting with the CBG.  Residues 116 through 136 are where the 
largest structural differences are located between these two cyclins.  [Reprinted with permission from Liu, 
S., J. K. Bolger, et al. (2010). "Structural and Functional Analysis of Cyclin D1 Reveals p27 and Substrate 
Inhibitor Binding Requirements." ACS Chemical Biology 5(12): 1169-1182.. Copyright 2010 American 
Chemical Society.] 
21 
with the aim of generating a cell permeable, non-peptidic inhibitor.   
 
 
Advantages of the REPLACE strategy are that non-peptidic fragments can be 
identified for extensive and shallow PPIs while negating the need for highly sensitive 
binding assay and should be applicable in the replacement of individual amino acids or 
peptide sequences to generate pharmaceutically adequate lead molecules
10b
. 
REPLACE has previously been utilized to replace the N-terminal amino acids 
FIGURE 1.8. COMPARING THE PRIMARY AND SECONDARY HYDROPHOBIC POCKETS OF THE CBG OF 
CYCLIN A AND CYCLIN D1. Solvent accessible representations of the cyclin binding groove.  (Left) Cyclin 
A2 was determined to have a more acidic region around GLU220 of the CBG causing ARG4 of the CBM 
to interact differently in cyclin A2 compared to cyclin D1.  (Right) Cyclin D1 was determined to have a a 
shallower and an extended primary hydrophobic pocket and a narrower secondary hydrophobic pocket 
compared to cyclin A2. These structural differences promote different binding affinities for CBG 
inhibitors.  [Reprinted with permission from Liu, S., J. K. Bolger, et al. (2010). "Structural and Functional 
Analysis of Cyclin D1 Reveals p27 and Substrate Inhibitor Binding Requirements." ACS Chemical 
Biology 5(12): 1169-1182.. Copyright 2010 American Chemical Society.] 
FIGURE 1.9. REPLACE METHODOLOGY.  A schematic overview of the REPLACE strategy.  The lead 
peptide is truncated at the N-terminus and computationally designed partial ligand alternatives (PLAs) are 
coupled through solid-phase peptide synthesis.  These FLIP compounds are then tested in a competitive 
binding assay and those with substantial activities are further optimized by the truncation and replacement 
of the central and C-terminal amino acids resulting in a cell permeable, non-peptidic inhibitor.   
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(HAKR) with fragment molecules (Ncaps) to create FLIPs
3, 10b
.  Much progress has been 
made in the replacement of these amino acid residues.  The most potent Ncap to date is 1-
(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (35DCPT) which has 
decreased the overall charge of the peptidic sequence by eliminating the charged Arg4 
residue and has improved potency compared to other FLIP compounds
10b
.  When coupled 
to RLIF (SCCP 5773; Table 1.2), the FLIP compound showed an IC50 value of 4.0±0.6 
µM against CDK2/cyclin A and 27.3±3.40 µM against CDK4/cyclin D1
3, 35
.  These 
values were directly compared to an optimized peptide sequence that contains the C-
terminal amino acids RRLIF of HAKRRLIF
3
.  This pentapeptide has an IC50 value of 1.4 
µM against CDK2/cyclin A and 16.1 µM against CDK4/cyclin D1
3
.  
TABLE 1.2.  Summary of Previously Reported N-terminal Capping Groups Coupled with RLIF.   
 
 
SCCP 
ID R1 R2 R3 R4 W X Y Z 
CDK2/cyclin A 
IC50 (µM) 
CDK4/cyclin D1 
IC50 (µM) 
5773 Cl H Cl Me N N N C 4.0±0.6 27.3±3.40 
5774 H Cl H Me N N N N 11.5±3.3 12.0±2.06 
 
Many heterocyclic compounds were designed for the replacement of HAKR and 
tested against these two cyclins.  Such compounds include but are not limited to triazole, 
pyrazole, pyrrole, furan, imidazole, and thiazole
3, 35
.  Variants of each heterocycle were 
generated with halogens at either the three and five position or at the fourth position of 
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the phenyl ring
3
.  These substitutions were demonstrated to have a significant impact on 
the binding affinity of these FLIP compounds as measured using a fluorescence 
polarization assay.  The phenyltriazole compounds were determined to be the most 
potent
3
.  A second phenyltriazole FLIP, SCCP 5774, (4-chlorophenyl triazole-RLIF; 
4CPT; Table 1.2) was shown to have greater activity in cyclin D1 compared to SCCP 
5773 with IC50 values of 11.5±3.3 µM and 12.0±2.06 µM against CDK2/cyclin A and 
CDK4/cyclin D1, respectively
3, 35
.  The narrower secondary pocket of cyclin D1 cannot 
accommodate the 3,5-dichlorophenyl ring of SCCP 5773 to the same degree as the 4-
chloro substituted analog
3
.  This data demonstrates that critical residues of the octamer 
can be replaced with small drug-like molecules while decreasing overall charge and 
increasing potency
9a
. 
Viable Ncaps have been identified and fragment alternatives are now desired for 
the replacement of the central and C-terminal amino acids, RLIF, to complete the 
conversion of HAKRRLIF into a more drug-like molecule.  A library of bis(aryl) 
compounds were generated and it was determined that Ccaps containing a 3-
phenoxybenzylamine core structure were the most effective at mimicking the binding 
mode of Phe8
3
.  Structural modifications were conducted to determine how activity could 
be optimized further and halogens were added at various positions of the aromatic ring 
contacting the primary hydrophobic pocket
3
.  It was determined that the FLIP compound 
containing a fluorine at the four position of the bis(aryl) Ccap, with 4CPT as Ncap and an 
arginine linker (SCCP 5823) was the most potent against CDK2/cyclin with an IC50 value 
of 18.1±4.0 µM
3
 (Table 1.3).  However, neither this FLIP nor others generated have been 
potent against CDK4/cyclin D1.   
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TABLE 1.3.  Summary of Two Previously Reported Fragment Ligated Inhibitory Peptides. 
 
 
SCCP 
ID R1 X R2 R3 R4 R5 
CDK2/cyclin A 
IC50 (µM) 
CDK4/cyclin D1 
IC50 (µM) 
5823 4CPT N H H F H 18.1±4.0 >200 
5926 35DCPT N H F F H >180 >180 
 
The replacement of Leu6 and Phe8 is imperative for the conversion of HAKRRLIF 
to a more drug-like molecule based on the work of Liu et al. (2013).  Small molecule 
replacements, to enhance the binding affinity of the FLIP molecule, are desired and the 
following chapters describe further applications of the REPLACE strategy for the design 
of such novel Ccaps.  Towards this goal, computational design has been utilized for 
structure- and pharmacophore-based design of Leu6 and Phe8 replacements.  In addition 
non-natural arginine isosteres have been incorporated to retain and/or enhance the 
binding affinity of FLIP compounds while making them more drug-like.  Achieving this, 
will be progressive towards the complete replacement of HAKRRLIF resulting in more 
drug-like compounds that should have enhanced cell permeability and carry this project 
into the next phase of in vivo testing of such compounds.  
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CHAPTER 2 
DESIGN OF FRAGMENT LIGAND INHIBITORY PEPTIDES FOR THE REPLACEMENT 
OF THE C-TERMINAL AMINO ACIDS OF THE CYCLIN-BINDING MOTIF
 
In the effort to convert HAKRRLIF into a more drug-like molecule by utilizing the 
REPLACE methodology, the replacement of the N-terminal amino acids (HAKR) has 
been undertaken and significant progress has been achieved.  The most effective FLIP 
compound for the replacement of HAKR to date is 1-(3,5-dichlorophenyl)-5-methyl-1H-
1,2,4-triazole-3-carboxamide (35DCPT)-RLIF (SCCP 5773; Table 1.2).  However, 
further replacement of the C-terminal residues (RLIF) is required for the complete 
conversion of HAKRRLIF into a cell permeable, non-peptidic inhibitor.  A library of 
bis(aryl) ether fragments, coupled with Ncap-Arg5-Leu6 (i.e. the 5
th
 and 6
th
 amino acids 
of HAKRRLIF), has shown activity in the mid to high micromolar concentrations in 
inhibiting CDK2/cyclin A.  The most potent of these compounds was found to be 4-(4-
fluorophenoxy)pyridin-2-yl)methanamine coupled to 1-(4-chlorophenyl)-5-methyl-1H-
1,2,4-triazole-3-carboxamide (4CPT)-RL (SCCP 5823, Figure 2.1) which has an IC50 
value of 18.1±4.0 µM against CDK2/cyclin A but no appreciable activity towards 
CDK4/cyclin D1.  Further optimization to obtain a more effective C-terminal capping 
group is required for the conversion of HAKRRLIF to a more drug-like, cell permeable 
small molecule.  Currently the Ccaps that have been developed are weakly or not active 
against CDK2/cyclin A or CDK4/cyclin D1.  A new approach for the design and 
development of such novel Ccaps for the replacement of RLIF of the octamer is desired.  
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To achieve this, computational design has been used to identify small molecules of 
interest via structure-based design with Discovery Studio 3.0 and the web-based 
pharmacophore search software AnchorQuery™.   
 
2.1 PICOLINAMIDE AND BENZAMIDE NCAP SCAFFOLDS 
To continue with the replacement of the amino acid residues of HAKRRLIF, 
picolinamide and benzamide Ncaps were used to perform substructure searches of online 
libraries for diverse small molecules that can be used to replace the entire octapeptide 
(HAKRRLIF) or be used to design potential Ccaps for the replacement of RLIF.  The 
picolinamide and benzamide Ncaps (Figure 2.2) have been modeled and show to have 
similar intermolecular interactions as the triazole derivative 35DCPT with the CBG at 
Trp217 and Glu254.  These two interactions are of importance to help retain the binding 
affinity for the FLIP compounds.  When tested in a competitive binding assay, 
picolinamide and benzamide showed adequate IC50 values comparable to those of 
35DCPT.  When coupled with RLIF, 35DCPT (SCCP 5773; Table 1.2) has IC50 values of 
4.0±0.6 µM against CDK2/cyclin A and 27.3±3.4 µM against CDK4/cyclin D1.  To date 
the most potent picolinamide derivatives, coupled with RLIF, are 6-methoxypicolinamide 
(SCCP 524) with an IC50 value of 70.1±7.9 µM against CDK2/cyclin A and 5-(piperazin-
1-ylmethyl)picolinamide (SCCP 5856) with an IC50 value of 42.7±12.02 against 
FIGURE 2.1.  CHEMICAL STRUCTURE OF SCCP 5823.  Chemical structure of 1-(4-chlorophenyl)-N-((S)-
1-(((R)-1-(((4-(4-fluorophenoxy)pyridin-2-yl)methyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-5-
guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5823). 
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CDK4/cyclin D1.  Also, to date the most potent benzamide derivative is 3-hydroxy-4-
(piperazin-1-ylmethyl)benzamide coupled to R(β-Leu)N-Methyl-Phe-NH2 (SCCP 5966) 
has been shown to have IC50 values of 3.91 µM and 4.93 µM against CDK2/cyclin A and 
CDK 4/cyclin D1, respectively.  Changing the C-terminal amino acids from RLIF to R(β-
Leu)N-Methyl-Phe-NH2 increased the binding affinity for this FLIP compound 1.5-fold. 
 
A library search using these Ncap as scaffolds has identified potential Ccaps of 
which the small molecules are commercially available.  This allows rapid assessment of 
activity without investing the time, expense and effort in the laboratory required to 
synthesize these compounds.  Using this approach, small molecules identified to replace 
HAKRRLIF are required to have at least one of the desired hydrogen bonding (H-
bonding) interactions in the secondary hydrophobic pocket (Trp217 and/or Glu254) to 
help retain the binding affinity of HAKR and have good complementarity with the 
primary hydrophobic pocket for the replacement of RLIF.  Of the small molecules 
identified, those with the best prediction will be sourced commercially and their activities 
tested in a competitive binding assay.   
2.1.1 RESULTS AND DISCUSSION 
Previously, validation exercises for LigandFit as a high throughput docking method were 
conducted to determine the predictability and reproducibility of computationally 
FIGURE 2.2. CHEMICAL STRUCTURES OF N-TERMINAL CAPPING GROUPS. Chemical structures of (left) 
1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide  (35DCPT), (middle) picolinamide, 
and (right) benzamide.  
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designing Ccaps.  Along with a negative control, native ligands of both cyclin A and 
cyclin D (35DCPT and 4CPT, respectively) were used as positive controls and docked 
into the CBG of CDK2/cyclin A.  In conjunction with this docking, a number of 
parameters were altered such as a) the energy grid (force field that calculates the ligand-
receptor interaction energies), b) the minimization sphere (helps minimize the molecular 
energy), and c) the number of poses (orientation of how the fragment potentially may fit 
into the pocket) generated.  For each of the result sets, the poses generated that were 
superimposable with the native ligand crystal structure (correct poses; within 2 
Angstroms), whose scoring functions (used to provide a consistent interpretation of the 
data generated) yielded the negative control to be within the top 25 poses, and whose 
scoring functions yielded the most number of correct poses within the top 25 poses were 
further studied.  The CFF (consistent force field) energy grid with the minimization 
sphere on, the generation of 20 poses per native ligand, and the scoring functions of 
LigScore2_Dreiding, -PLP1, and –PLP2 were determined to be the optimized parameters 
for the LigandFit docking method (Table 2.1).   
Picolinamide and benzamide Ncap scaffolds were used in a substructure search of 
the ChemBridge® library for potential small molecules to replace HAKRRLIF or to aid 
in the design of novel Ccaps.  The validated optimized parameters were used in the 
docking of the resulting compounds from the search.  One of the most interesting 
fragments is N-(5-guanidino-1-(naphthalen-2-ylamino)-1-oxopentan-2-yl)benzamide 
(BZ01; Figure 2.3) which contains a benzamide Ncap, a naphthalene Ccap, and an 
arginine in the Arg5 position.   
The benzamide Ncap, of this small molecule, forms an H-bond with Trp217 and the 
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arginine ion-pairs with Asp283 and H-bonds with Glu254.  In addition, the naphthalene 
Ccap has good complementarity with the primary hydrophobic pocket.  This compound 
also ranks well in the overall scoring functions.  LigScore2_Dreiding, -PLP1, and –PLP2 
were previously determined to be the optimal scoring functions for the prediction of 
potent small molecules.  This compound is ranked within the top twenty- five percent of 
all ligands docked with scores of 5, 56.06,and 55.88 for LigScore2_Dreiding, -PLP1, and 
–PLP2, respectively (Table 2.2).  With the observed intermolecular interaction and the 
resulting scores, this molecule was expected to have activity against both Cyclin A and 
D1.  However, upon testing in the FP assay this fragment was found to be weakly 
binding.  Possible further optimization of the naphthalene group would provide better 
binding. 
TABLE 2.1 VALIDATION RESULTS FOR THE SELECTION OF OPTIMAL PARAMETERS FOR THE LIGANDFIT 
DOCKING METHOD 
 
Energy Grid Dreiding CFF PLP1 
No. of correct poses 
3,5-DCPT 
7 10 7 
No. of correct poses 
4-CPT 
3 - 1 
Negative controls in 
top 25  
-PLP1(5), -PLP2(3), 
PMF(10), DOCK 
SCORE(4) 
-PMF (21) -PLP1(1), -PMF(10) 
Best scoring functions  
LigScore2_Dreiding, -
PLP1, 
-PLP2, DOCKSCORE 
LigScore2_Dreiding, 
-PLP1, -PLP2 
LigScore2_Dreiding, 
-PLP1, -PLP2, 
DOCKSCORE 
3,5-DCPT(rank of top 
25 correct/closer 
poses for the best 
scoring function) 
LigScore2_Dreiding, 
-PLP1, -PLP2, and 
DOCKSCORE (22,23,24, 
25,26,27), Jain (22) 
LigScore2_Dreiding, 
-PLP1, and –PLP2 
(31,32,33,38) 
LigScore2_Dreiding, 
-PLP1, and –PLP2 
(39,40,41), 
DOCKSCORE 
(23,28,29,30) 
4-CPT (rank of top 
25 correct/closer 
poses for the best 
scoring function) 
- 
-PLP1 (11,14,15), 
Jain (11), 
-PMF 
(11,12,13,14,15) 
-PLP1 (6), -PMF 
(8,21) 
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The most potent benzamide Ncap coupled with RLIF contains a 4-
methoxypiperidine (SCCP 5851) at the 4 position of the aromatic ring.  This functional 
group and others can easily be added to the benzamide to help retain activity against 
Cyclin A and D1.  Various groups also may be added to the naphthalene Ccap to 
potentially promote further intermolecular interactions and increase the binding affinity.   
TABLE 2.2.  The SCORING FUNCTION SUMMARY FOR N-(5-GUANIDINO-1-(NAPHTHALEN-2-YLAMINO)-1-
OXOPENTAN-2-YL)BENZAMIDE [BZ01], METHYL 3-BENZAMIDO-5-((5-METHYL-3-PHENYLISOXAZOLE-4-
CARBOXAMIDO)METHYL)BENZOATE [BZ02], (E)-N-(3-((1,5-DIMETHYL-3-OXO-2-PHENYL-2,3-DIHYDRO-
1H-PYRAZOL-4-YL)AMINO)-3-OXO-1-PHENYLPROP-1-EN-2-YL)BENZAMIDE [BZ03]. 
 
Scoring Function BZ01 BZ02 BZ03 
LigScore2_Dreiding 5 5.38 5 
-PLP1 56.06 101.82 68.54 
-PLP2 55.88 90.39 63.07 
 
A second fragment that is of interest is methyl 3-benzamido-5-((5-methyl-3-
phenylisoxazole-4-carboxamido)methyl)benzoate (BZ02; Figure 2.4) which contains the 
benzamide Ncap, a 5-methyl-3-phenylisoxazole-4-carboxamide Ccap, and benzoate in 
GLU254 
TRP217 
FIGURE 2.3. POTENTIAL SMALL MOLECULE FOR THE REPLACEMENT OF HAKRRLIF (BZ01).  N-(5-
guanidino-1-(naphthalen-2-ylamino)-1-oxopentan-2-yl)benzamide modeled into the CBG of cyclin A 
(BZ01; PDB 2UUE).  As shown by the light green dotted lines, this small molecule hydrogen bonds and 
ion-pairs with the CBG at TRP217, GLU254, and ASP283, respectively. 
ASP283 
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place of Arg5.  The benzamide Ncap H-bonds with Trp217 and this molecule scores 
within the top twenty-five percent with scores of 5.38, 101.82, and 90.39 for 
LigScore2_Dreiding, -PLP1, and –PLP2, respectively (Table 1.1).   
 
The scores for this fragment rank higher than BZ01 however, BZ02 may not retain 
the binding affinity as well.  The benzoate linker is unable to ion-pair with Asp283 
similarly to Arg5 and the 5-methyl-3-phenylisoxazole-4-carboxamide Ccap does not 
mimic the binding mode of Leu6 and Phe8 well.  However, the lack of these interactions 
has not been determined to be detrimental to the binding affinity and thus would be worth 
testing to determine the activity this fragment has against both CDK2/cyclin A and 
CDK4/cyclin D1.  
Another compound that is of interest is (E)-N-(3-((1,5-dimethyl-3-oxo-2-phenyl-
2,3-dihydro-1H-pyrazol-4-yl)amino)-3-oxo-1-phenylprop-1-en-2-yl)benzamide (BZ03; 
Figure 2.5).  This molecule contains the benzamide Ncap, a 4-amino-1,5-dimethyl-2-
phenyl-1H- pyrazol-3(2H)-one Ccap and 3-phenylacrylaldehyde in place of Arg5.  This 
fragment H-bonds with Trp217 and ranks within the top twenty-five percent of the 
FIGURE 2.4. POTENTIAL SMALL MOLECULE FOR THE REPLACEMENT OF HAKRRLIF (BZ02). Methyl 3-
benzamido-5-((5-methyl-3-phenylisoxazole-4-carboxamido)methyl)benzoate [BZ02] modeled into the 
CBG of cyclin A (PDB 2UUE).   
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ligands docked.  This molecule has scores of 5, 68.54, and 63.07 for LigScore2_Dreiding, 
-PLP1, and –PLP2, respectively (Table 1.1).  Compared to BZ01 this fragment also ranks 
higher in all scoring functions however, this molecule is also not expected to retain the 
binding affinity of HAKRRLIF.  The 3-phenylacrylaldehyde linker acts more as a spacer 
and theoretically does not interact with the CBG similarly to Arg5.  The 4-amino-1,5-
dimethyl-2-phenyl-1H-pyrazol-3(2H)-one Ccap looks to mimic the binding mode of 
Leu6 and Phe8 better than that of BZ02 and potentially may help retain the binding 
affinity of these residues.   
In addition to potential replacements for HAKRRLIF, this exercise helped 
generate ideas for the design of novel Ccaps.  From BZ01, it is evident that a fused ring 
system, like naphthalene (Figure 2.6), fits well into the primary pocket and many analogs 
of this Ccap can be generated.  A few modifications can be alkylation or halogenation to 
help the Ccap reach further into the pocket and potentially enhance the binding mode of 
these analogs.  Another compound identified from ChemBridge® was an adamantane 
derivative.  This compound is also adequate for this pocket and would most likely mimic 
the binding mode of Phe8 but this group is bulky and may not be suitable for the Leu6 
position.  Modifications of the adamantane can also be generated by alkylation or 
halogenation to retain/enhance the binding affinity of the FLIP compound incorporating 
this Ccap.  An alkylated furan group may also be of interest for the replacement of LIF.  
The five-membered ring will provide a different geometry in the pocket which may 
benefit the binding affinity and help generate further SAR.   
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Obtaining the IC50 values for BZ02 and BZ03 will beneficial to the investigation of 
prospective replacements for HAKRRLIF.  BZ01 was determined to be weakly binding 
and shows that a fused ring system alone may not be sufficient in the primary pocket and 
that further optimization of this group is needed to regain activity.  The ideas generated 
from this exercise for potential Ccaps have been taken into consideration and the future 
design of Ccap may incorporate such scaffolds.   
2.1.3 MATERIAL AND METHODS 
Small molecules identified through the ChemBridge® library search that are of most 
interest, have been/will be purchased and tested in a competitive binding assay.  The 
FIGURE 2.5. POTENTIAL SMALL MOLECULE FOR THE REPLACEMENT OF HAKRRLIF (BZ03). (E)-N-(3-
((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)-3-oxo-1-phenylprop-1-en-2-yl) 
benzamide [BZ03] modeled into the CBG of cyclin A (PDB 2UUE).   
FIGURE 2.6. CHEMICAL STRUCTURES OF CCAP SCAFFOLDS.  Chemical structures of adamantane, furan, 
and naphthalene amine derivatives as scaffolds for Ccap designs. 
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Florescence Polarization (FP) assay was used to evaluate the small molecule’s ability to 
compete with a florescence labeled ligand, known as tracer, against CDK2/cyclin A and 
CDK4/cyclin D1.  This assay monitors the changes in molecular interactions in 
fluorescent molecules
39
.  This type of analysis is advantageous because it allows for 
direct and rapid measurements of the ratio of bound and free tracer peptide
39
  The FP 
assay is conducted in solution allowing for true equilibrium analysis into the low 
picomolar range and real time measurements
39
.   
 The theory behind the FP assay is that small fluorescent molecules become excited 
via plane-polarized light.  When the tracer is bound to the protein, the rotation is slower 
and the emitted light is in the same plane at the excitation energy therefore, giving off a 
higher fluorescence
39
.  Polarization is then calculated by measuring the molecular 
rotation during the time between excitation (488 nm) and emission (535 nm)
39
.  The 
equation used for calculating the relative polarization (mp) is as follows: 
 
The IC50 values are then determined by using a logarithmic regression of the relative mp 
values versus the testing concentrations
3
. 
The FP assay was conducted as previously reported
3
.  In brief, buffer solution, 
tracer peptide, positive and negative controls, the protein, and the FLIP compound are 
combined in 384-well plates and the fluorescence of each well is measured by a Beckman 
Coulter DTX 880 Multimode detector.  The C-terminal pentapeptide of the endogenous 
p21
WAF1
 (RRLIF) was previously tested in the FP assay and showed IC50 values of 1.4 
μM and 16.1 µM for CDK2/cyclin A and CDK4/cyclin D1, respectively3.  The binding 
EQ 2.1 
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affinity for CDK2/cyclin A and CDK4/cyclin D1 of the Ccaps generated will be directly 
compared the binding affinity of these native ligands.   
2.2 PHARMACOPHORE BASED DESIGN 
Studies using the AnchorQuery™ pharmacophore search technology software have been 
conducted for the development of potential Ccaps.  AnchorQuery™ is an online software 
program that runs from a webserver that allows pharmacophore features of a peptide 
sequence to be specified and small molecules from a Multi-Component Reaction (MCR) 
database that closely mimic the pharmacophore of interest be returned by the software for 
further analysis.  For this study, HAKRRLIF and the receptor (cyclin A) were uploaded 
into the software and the desired pharmacophore queries of the C-terminal amino acids 
(RRLIF) were varied to allow the maximum number of potential small molecules to be 
returned by the software.  Example pharmacophore queries include aromatic, hydrogen 
bond donor, hydrogen bond acceptor, hydrophobic and positive-ion searches.  Two types 
of anchors (leucine/valine and phenylalanine) were used to aid in the preservation of side 
chains functionality required for binding in the peptide context.  An anchor is defined as a 
functional group that chemically mimics a specific amino acid
40
.  Other filters that may 
be set include specific types of reaction used for synthesis, molecular weight in Daltons, 
rotatable bond count, or the root mean squared deviation (RMSD; to minimize the 
compounds returned by the software to those containing the conformation within the 
query features that were selected) can be varied to help obtain fragments that are of most 
interest.  The molecules returned by the software are all accompanied with the 
information regarding their synthesis via MCR.  Using this strategy, fragments identified 
should closely match the pharmacophore of the native ligand in order to retain critical 
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peptide binding determinants and increase the probability of finding an active Ccap.   
2.2.1 RESULTS 
Using this approach, Ccaps of interest have been identified and synthesized.  One 
of the most interesting Ccaps predicted by the software is 2-amino-N-ethyl-4-methyl-N-
(3-phenylpropyl)pentanamide (Ccap in SCCP 6005 and 6014; Table 2.4), Figure 2.7 
illustrates this capping group superimposed with HAKRRLIF in the primary hydrophobic 
pocket of Cyclin A.  From this image, it is evident that the phenyl propylamine group 
closely mimics the interactions of Phe8.  The predicted binding mode of this group 
suggests that when incorporated as a FLIP, this compound will aid in retaining the 
binding affinity of RRLIF in the primary hydrophobic pocket.  This synthesis of this 
small molecule was suggested by AnchorQuery™ to be achieved using a reductive 
amination MCR however, it was determined that synthesis via a two-step process had 
better versatility and allowed facile incorporation of the Ncap and arginine residues.  This 
fragment, 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)pentanamide, was synthesized 
via reductive amination followed by peptide synthesis (Scheme 2.1) and purified through 
semi-preparative High Performance Liquid Chromatography (prep-HPLC).  Prep-HPLC 
and Mass Spectroscopy (MS) data can be found in Appendix A.  
In addition to 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)pentanamide, other 
variations  have also been synthesized (Table 2.3).  Each of these Ccaps have been 
coupled to 35DCPT-Arg and either Leu or Beta-Leu (Figure 2.8).  The variations (Table 
2.3) include different length alkyl chains, and a hydrogen or ethyl group at the R position.  
The natural leucine was used in the synthesis of the analogs with a propyl alkyl chain 
(SCCP 6004, 6005, and 6014).  Natural leucine, with the amine group on the alpha 
 37 
carbon, helps position these Ccaps in a binding mode similarly to that of the native 
ligand, aids in the positioning of these fragments in the primary hydrophobic pocket, and 
potentially aids in retaining the binding affinity of LIF.  Non-natural β-leucine was used 
in the synthesis of the analogs with either methylene or ethylene alkyl chains (SCCP 
6000, 6001, 6002, and 6003).  Beta amino acids contain an additional methylene group, 
placing the amine group on the beta carbon, which theoretically should adjust for the 
shorter alkyl chains and help position the fragments in the primary hydrophobic pocket to 
closely mimic the native ligand.   
TABLE 2.3. SUMMARY OF CCAPS IDENTIFIED VIA THE ANCHORQUERY™ SOFTWARE. 
 
 
   
SCCP ID n1 n2 R 
CDK2/Cyclin A 
IC50 (µM) 
CDK4/Cyclin D1 
IC50 (µM) 
6000 1 1 H >180 >180 
6001 1 1 Et >180 >180 
6002 1 2 H >180 >180 
6003 1 2 Et 85.62 >180 
6004 0 3 H 57.74 >180 
6005 0 3 Et >180 >180 
6014 0 3 Et 90.19 >180 
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Following the peptide synthesis of Ncap-Arg-Leu/βLeu the Ccaps of Table 2.3 
were coupled followed by the deprotection of these guanidine protecting group of 
arginine and the purification of these FLIP compounds through prep-HPLC.  The HPLC 
data and MS data of the purified FLIPs are located in Appendix A.  As shown by the 
HPLC traces, the FLIPs are 88-98 percent pure, by UV, and the MS results confirm the 
identity of the desired FLIP.  Once the FLIP compounds were characterized, their binding 
affinities were tested by FP assay as described in Section 2.1.4.  The competitive binding 
assay determined that the ethyl phenylethan-amine Ccap coupled to 35DCPT-R-β-L 
(SCCP 6003, Table 2.3) has an IC50 value of 85.62 µM and the phenylpropyl amine and 
ethyl phenylpropyl amine Ccaps, coupled with 35DCPT-RL (SCCP 6004 and 6014 
respectively), have an IC50 values of 57.74 µM, and 90.19 µM against CDK2/cyclin A, 
respectively.  All other FLIP compounds in Table 2.3 have IC50 values greater than 180 
µM against CDK2/cyclin A. 
FIGURE 2.7. NOVEL C-TERMINAL CAPPING GROUP FOR THE REPLACEMENT OF LIF.  2-amino-N-ethyl-
4-methyl-N-(3-phenylpropyl)pentanamide superimposed with LIF of the CBM in the primary hydrophobic 
pocket.  This small molecule mimics the exact poses of LEU6 and PHE8 in this pocket and thus several 
derivatives of this small molecule have been designed and tested in a competitive binding assay to 
determine their binding affinity. 
 39 
 
 
2.2.2 DISCUSSION 
The replacement of the C-terminal tetrapeptide (RLIF) is necessary for the complete 
conversion of HAKRRLIF to a non-peptidic, drug-like inhibitor.  The pharmacophore of 
SCHEME 2.1. SYNTHESIS OF THE NOVEL C-TERMINAL CAPPING GROUPS.  This scheme illustrates the 
route of synthesis for the novel C-terminal capping groups.  First the amine underwent reductive amination 
to form a secondary amine.  Second, the Ncapped peptide was made using solid phase synthesis.  Next, the 
secondary amine was coupled to the Ncapped peptide in a solution phase coupling reaction.  In the final 
step, the arginine side chain was deprotected. 
CCAP SYNTHESIS 
SOLID PHASE SYNTHESIS 
FIGURE 2.8. CHEMICAL STRUCTURES OF LEUCINE AND BETALEUCINE.  Chemical structures of natural 
leucine and non-natural β-Leucine. 
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(R)RLIF was utilized in the AnchorQuery™ software to screen for potential fragment 
alternatives for the replacement of this peptide sequence.  The AnchorQuery™ software 
is of interest because it specializes in pharmacophore search technology to help users 
screen for novel PPIs
40
.   
A library of potential C-terminal capping groups have been identified, through 
AnchorQuery™, that contains the desired pharmacophore features while maintaining 
good complementarity with the primary hydrophobic pocket of the CBG.  Mimicking and 
preserving the binding determinants of Leu6 and Phe8 is of utmost importance because 
these particular residues make important intermolecular interactions with the CBG.  
Other important interactions between the CBM and the CBG are the H-bonding of Arg4 
with Ile281 and ion-pairing interactions of this residue with Glu220, H-bonds between 
Arg5 and Gln254 and charge-charge interactions with Asp283.  In addition, the backbone 
amide of Leu6 H-bonds with Gln254 while Ile7, of the CBM, acts as a spacer between 
Leu6 and Phe8, allowing complementary binding of these two residues in the primary 
hydrophobic pocket (Figure 2.9).  P 
otential Ccaps for the C-terminal tripeptide LIF have been identified using the 
AnchorQuery™ software.  HAKRRLIF and the receptor (cyclin A) were uploaded into 
the software and the desired pharmacophore queries of the C-terminus were set.  Figure 
2.10 illustrates the pharmacophores that were varied to maximize the number of 
potentially viable small molecules returned by the software.  In addition, other filters 
were applied and varied to refine the fragments returned by the software to those that 
most closely mimic the pharmacophore queries of interest.  A LeuVal anchor was used to 
preserve the side chain functionality of the Leu6 because it was previously determined 
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that this residue is the most critical residue in the CBM
10b
.  Once the preferred 
pharmacophore queries (maximum of 20) and filters were set, the query was submitted 
and the software searched upwards of 25 million compounds to find small molecules that 
were within the specified parameters.  The fragments returned by the software can be 
viewed interactively on the website or be downloaded as .sdf files to be viewed in 
preferred software.   
 
The AnchorQuery™ website contains sufficient information for the synthesis of the 
potential capping groups.  The fragments returned by the software are categorized by the 
type of reaction that can be used for their synthesis.  The small molecules in the database 
are part of a MCR library and these reactions differ from standard sequential syntheses in 
that the desired product may be obtained by a “one-pot” method using three or more 
starting materials. The single step used has obvious benefits in saving on time and cost 
GLN224 
TRP217 
ASP283 
ILE281 
GLU220 
GLN254 
FIGURE 2.9. HAKRRLIF DOCKED INTO THE CBG.  The intermolecular interactions of the CBM with the 
CBG are illustrated here indicated by the light green dotted lines.  The known intermolecular interacts are 
as follows: histidine ion-pairs with GLU224, alanine hydrogen bonds with TRP217, the first arginine 
hydrogen bonds with ILE281 and GLN254 as well as ion-pairs with GLU220, the second arginine ion-pairs 
with ASP283, and leucine hydrogen bonds with GLN254. 
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and the overall yield, simplicity of reaction and purification, safety, and environmental 
acceptability
41
.  In MCRs, the starting materials react sequentially rather than at the same 
time and it is the irreversible steps that drive the reaction to completion.  With MCRs, 
more time is spent on the design and development of the experiment compared to 
traditional sequential reactions.  The most common MCR is the Ugi Reaction (Scheme 
2.2).  This MCR is a four component reaction that includes an acid component, aldehyde 
or ketone, amine component and an isocyanide component
41
.  In the initial step, the 
aldehyde or ketone and the amine components condense to form an intermediate imine, 
followed by protonation of the acid component to increase the electrophilicity of the 
imine bond
41
.  The electrophilic iminium ion and the now nucleophilic conjugate base of 
the acid, add to the isocyanide component forming an intermediate acid anhydride (not 
shown).  Acid anhydrides are strong acylating agents and following intramolecular 
acylation and rearrangement of the hydroxylimine intermediate to an amine the stable 
Ugi product is formed
41
.   
Previously it has been reported that RRLIF (SCCP 5811, Table 2.4) has an IC50 
value of 1.4±0.42 µM against CDK2/cyclin A and when Arg4 (the first Arg of RRLIF) 
was replaced with 35DCPT (SCCP 5773, Table 1.2) the potency decreased by two-fold to 
give an IC50 value of 4.0±0.6 µM against CDK2/cyclin A.  Also, RRLF (SCCP 5874; 
Table 2.4) was reported to have an IC50 value of 24.8±12.66 µM, a decrease in potency of 
approximately twelve-fold, against CDK2/cyclin A.  Theoretically, if Arg4 (the first Arg 
of RRLF) of SCCP 5874 was replaced with 35DCPT (35DCPT-RLF), the IC50 value of 
this FLIP compound would be near 50 µM against CDK2/cyclin A.  The novel Ccap, 
phenylpropyl amine containing FLIP (SCCP 6004; Table 2.3) mimics the binding mode 
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of Phe8 and is structurally comparable to the hypothetical structure of 35DCPT-RLF.  
SCCP 6004 has an IC50 value of 57.74 µM against CDK2/cyclin A which is comparable 
to that of the theoretical IC50 value of 35DCPT-RLF of approximately 50 µM.  This 
concludes that SCCP 6004 may be the best FLIP compound of this series and the 
aromatic ring can further be optimized to regain potency.   
 
 
SCCP 6014 differs from SCCP 6004 by a tertiary amine at the R position, seen in 
Table 2.3.  The added ethyl group was originally thought to aid in the 
FIGURE 2.10. ILLUSTRATIONS OF THE ANCHORQUERY™ PHARMACOPHORE QUERIES.  AnchorQuery™ 
images of the pharmacophore queries that were used for the pharmacophore search.  The variations in the 
query were as follows: A) Ala2
hydrophobic
, Arg4
positiveion
, Leu6
hydrophobic
, and Phe8
hydrophobic
, B) Ala2
hydrophobic
, 
Arg5
positiveion
, Leu6
hydrophobic
, and Phe8
hydrophobic
 C) Arg4
positiveion
, Leu6
hydrophobic
, and Phe8
hydrophobic
, D) 
Arg5
positiveion
, Leu6
hydrophobic
, and Phe8
hydrophobic
, and E) Leu6
hydrophobic
 and Phe8
hydrophobic
. 
SCHEME 2.2. ILLUSTRATION OF THE UGI REACTION.  The Ugi reaction is a four component reaction where 
an acid component, an aldehyde or ketone, an amine component and an isocyanide are combined to form the 
Ugi product. 
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geometry/conformation of this compound however, the addition of this group has 
abolished most of the activity that is shown by SCCP 6004.  The ethyl chain may hinder 
the activity by steric hindrance, causing a clash with the protein, and resulting in the 
lower potency of this FLIP.  Perhaps a methyl group would be a better substituent at this 
position.  With a methyl there would be less steric bulk and potentially would avoid a 
clash with the protein.  The methyl group would still structurally aid in the geometry of 
the compound. 
TABLE 2.4.  SUMMARY OF PREVIOUSLY REPORTED PEPTIDES AND THEIR ACTIVITY AGAINST 
CDK2/CYCLIN A AND CDK4/ CYCLIN D1. 
 
 
2.2.3 MATERIAL AND METHODS 
Individually, HAKRRLIF and cyclin A (PDB 2UUE) were uploaded into the 
AnchorQuery™ software, the desired pharmacophore queries of the C-terminal amino 
acids (RRLIF) and a LeuVal anchor were selected.  The hydrophobic pharmacophore of 
Ala2, Leu6, and Phe8 (the 2
nd
, 6
th
, and 8
th
 amino acids of the octamer) and the ion-pairing 
pharmacophore of Arg4 and Arg5 were varied to obtain numerous small molecules 
(Figure 2.10).  The capping groups returned by the software all closely mimic the binding 
mode of both Leu6 and Phe8.  Retaining the SAR of these amino acids is critical in 
identifying potential Ccaps to replace LIF of HAKRRLIF.   
 The initial compound synthesized from the fragments returned by AnchorQuery™ 
was 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl)pentanamide.  This small molecule 
SCCP ID Peptide 
CDK2/Cyclin A 
IC50 (µM) 
CDK4/Cyclin D1 
IC50 (µM) 
5811 RRLIF 1.4±0.42 16.1±1.73 
5874 RRLF 24.8±12.66 100~180 
5875 RR(βLeu)F 3.3±2.33 20.7±12.45 
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was synthesized in four steps (1) reductive amination, (2) solid phase synthesis, (3) 
solution phase coupling, and (4) arginine deprotection (Scheme 2.1).  In brief, in a round 
bottom the amine (5 mmol; 5EQ; 676.05 mg) and aldehyde (1 mmol; 1EQ; 44.05 mg) 
starting materials were coupled via reductive amination in the presents of sodium 
triacetoxyborohydride (NaBH(OAc)3); 1.4 mmol; 1.4EQ; 296.72 mg) reducing agent in 
dichloromethane (DCM).  The reaction was conducted at room temperature (RT) for two 
hours.  After which 2N sodium hydroxide (NaOH) was added to quench the reaction and 
the reaction was left to stir for an additional 10 minutes.  The organic and aqueous layers 
were separated and the organic layer was removed under reduced pressure and the 
product was dried under vacuum.  The monoalkylated product was then purified by prep-
HPLC yielding 74.7 mg (0.1%) of pure product.  MS (EI+) 163. 
 The Ncap, 35DCPT, was prepared by the following procedure.  To a solution of 
3,5-dichloroaniline (15 mmol; 1EQ; 2.430 g) in a round bottom in 10 mL of methanol 
was added 10 mL of 6N hydrochloric acid (HCl) at 0 degrees Celsius.  Sodium nitrite (30 
mmol; 2EQ; 2.070 g) was then slowly added as a solid.  The reaction mixture was stirred 
for 15 minutes at 0 degrees Celsius, after which sodium acetate was added as a solid to 
adjust the reaction to pH 5.  Subsequent to this, a solution of ethyl 2-chloroacetoacetate 
(15 mmol; 1EQ; 2.469 g) in 10 mL of methanol was added slowly while the temperature 
was maintained at 0 degrees Celsius, after which the reaction mixture was allowed to 
warm to room temperature and stirred for 12 hours.  The reaction was monitored for 
completion by thin-layer chromatography (TLC) with 20 percent ethyl acetate (EtOAc) in 
hexanes.  Methanol was then removed under reduced pressure, diethyl ether was added, 
and the organic layer was separated and washed with saturated sodium bicarbonate and 
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water prior to drying over sodium sulfate
3
.  The organic layer was concentrated and the 
product was dried under vacuum yielding 2.107 g (47.6%).  
1
H NMR (chloroform-d, 300 
MHz) δ (ppm) 8.2 (s, 1H), 7.1 (s, 2H), 7.0 (s, 1H), 4.36-4.43 (q, J = 5.46 Hz, 2H), 1.38-
1.43 (t, J = 7.05 Hz, 3H).   
 The second step for the synthesis of 35DCPT is as follows.  The step 1 product, 
ethyl 2-chloro-2-[2-(3,5-dichlorophenyl)hydrazono]acetate (7.129 mmol; 1EQ; 2.107 g), 
and acetaldehyde oxime (7.129 mmol; 1EQ; 0.421 g) were dissolved in toluene and 
heated to reflux for 2 h, after which triethylamine (7.129 mmol; 1EQ; 0.721 g) was 
added. The reaction was monitored by TLC with 20% EtOAc in hexanes. After 
completion, the reaction mixture was then concentrated and partitioned between EtOAc 
and water. The layers were separated and the aqueous layer was washed with EtOAc. The 
combined organic layers were washed with water and brine, dried with sodium sulfate, 
filtered, concentrated and dried under vacuum yielding 2.2818 g (50.7%)
3
. 1H NMR 
(chloroform-d, 300 MHz) δ (ppm) 7.43 (d, J = 9 Hz 3H), 2.57 (s, 3H).  
 The final step in the synthesis of 35DCPT is as follows.  The step 2 product, ethyl 
1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylate (7.602 mmol; 1EQ; 
2.282 g) was refluxed in NaOH (60.820 mmol; 8EQ; 2.433 g) in a 50/50 mixture of 
ethanol  and water for 2 h, and the reaction was monitored by TLC (35% EtOAC in 
hexanes). After completion, the reaction mixture was cooled, the alcohol was evaporated, 
and the mixture was diluted with water. The reaction mixture was acidified with 1 N HCl 
and stirred to precipitate the product yielding 1.032 g (25.3%). 1H NMR (chloroform-d, 
300 MHz) δ (ppm) 7.50 (s, 1H), 7.45 (s, 2H), 4.46−4.53 (q, J = 7.26 Hz, 2H), 2.62 (s, 
3H), 1.41−1.46 (t, J = 7.08 Hz, 3H). MS (EI+) 271. 
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Solid phase peptide synthesis was used for the synthesis of 35DCPT-Arg-β-Leu 
similar to Section 2.3.3 (Scheme 2.3).  In brief, Fmoc protected leucine (1.108 mmol; 
2EQ; 391.58 mg) in 5 mL of DCM (10 mL/1 gram resin) and a 2-chlorotrityl resin (0.554 
mmol; 1EQ; 480 mg) was mixed in a round bottom at room temperature with N,N-
Diisopropylethylamine (DIPEA; 5.54 mmol; 1EQ; 715.99 mg) for 5 minutes
42
.  After 
which another 1.662 mmol (1.5EQ; 215.06 mg) of DIPEA was added and mixed for an 
additional 60 minutes.  To endcap any unreacted 2-chlorotrityl groups, HPLC grade 
methanol (0.4 mL; 0.8mL/1 gram of resin) was added and stirred for 15 minutes.  The 
resin was then filtered and washed three times with DCM, twice with dimethylformamide 
(DMF), twice with DCM and three times with methanol
42
.  The resin was placed into a 
solid phase peptide ynthesis vessel and the Fmoc group of the Leu was deprotected using 
20 percent piperidine in DMF while nitrogen was bubbled into the vessel for stirring.  
After 30 minutes, the resin was filtered and washed thoroughly with DMF. 
The second amino acid, Fmoc-Arginine(Pmc) (1.108 mmol; 2EQ; 764.38 mg) was 
added to the vessel in the presence of a coupling agent (O-benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate , HBTU; 2.438 mmol; 4.4EQ; 924.587 mg) 
and a base, DIPEA (3.324 mmol; 6EQ; 429.59 mg) in DMF and was bubbled with 
nitrogen at room temperature for 4-6 hours.  Upon a negative ninhydrin test, the resin was 
filtered and washed several times with DMF.  The Fmoc group was deprotected using 20 
percent piperidine in DMF for 30 minutes.  The resin was filtered and washed with DMF.  
The Ncap, 35DCPT (1.108 mmol; 2EQ; 301.48 mg) was then added to the resin with 
HBTU (2.438 mmol; 4.4EQ; 924.587 mg) and DIPEA (3.324 mmol; 6EQ; 429.59 mg) in 
DMF and bubbled with nitrogen at room temperature for 4-6 hours.  When the reaction 
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was complete, the resin was thoroughly washed with DMF.  The resin was removed from 
the vessel and placed into a round bottom flask to be cleaved using 3-5 percent TFA in 
DCM for approximately three minutes.  The resin was filtered and rinsed until the resin 
returned to a yellow in color and the filtrates was collected and was removed under 
reduced pressure and left to dry under vacuum.  The product was purified through 
FLASH chromatography yielding 240.10 mg (54%).   
In a round bottom, the Ccap 2-amino-N-ethyl-4-methyl-N-(3-phenylpropyl) 
pentanamide (0.272 mmol; 2EQ; 36.78 mg) was coupled the 35DCPT-Arg(Pmc)-Leu 
(0.136 mmol; 1EQ; 110 mg) peptide in the presence of HBTU (0.299 mmol; 2.2EQ; 
113.47 mg) and DIPEA (0.408 mmol; 4EQ; 52.73 mg).  HPLC was used to monitor the 
reaction and upon completion the reaction mixture was concentrated and partitioned 
between EtOAc and water.  The aqueous layer was back extracted with EtOAc.  The 
organic layers were combined and washed with 1N sodium hydroxide (NaOH), 1N HCl, 
and brine (saturated sodium chloride solution).  The organic layer was dried with sodium 
sulfate (Na2SO4), filter, concentrated, and dried under vacuum.  Lastly, the side chain of 
the Arg was deprotected using 95:2.5:2.5 TFA:water:TIPS overnight.  Once the HPLC 
confirmed deprotection the solvents were removed under reduced pressure and the final 
product was purified by prep-HPLC resulting 36.0 mg (40%) of SCCP 6004.  MS (EI+) 
658. 
2.3 LEU-PHE MIMETICS 
Based on commercially available compounds with appropriate functionality to mimic 
both Leu6 and Phe8, FLIPs have been computationally designed (Table 2.5), synthesized 
and coupled to 35DCPT-Arg5.  These Leu-Phe mimetics contain either isobutyl or 
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isopropyl groups at the R2 position (Table 2.5) to help retain the interactions of Leu6 in 
the primary hydrophobic pocket which was shown to be the most important residue of the 
CBM.  Also, there are varying alkyl groups at the R1 position to mimic Phe8 in the 
pocket.   
2.3.1 RESULTS 
Following solid phase synthesis and coupling with the Ccap, the Leu-Phe mimetics 
were purified via prep-HPLC.  As these compounds have a chiral center and were 
purchased as a racemic mixture, diastereomers were formed for the FLIPs during 
synthesis.  However, not all of the FLIP isomers were able to be successfully separated 
by prep-HPLC but the diastereomers that were separated the first isomers that eluted 
were those that showed activity against CDK2/cyclin A.  The isomers with activity would 
be the R isomer, as the S isomer would not be expected to have activity against the 
CDK/cyclin complexes because only R amino acids have been shown to be active.  The 
HPLC data and MS data of the purified FLIPs are located in Appendix B.  As shown by 
HPLC, the FLIP compounds are 79-98 percent pure by UV and the MS results confirm 
the identity of desired FLIP compounds.  Subsequent to full characterization of the FLIP 
compounds their binding affinities were tested via FP assay as described in Section 2.1.4.  
Of the FLIPs listed in Table 2.5, only SCCP 5977, 5979 and 5983 showed activity 
against CDK2/cyclin A while none displayed significant binding to CDK4/cyclin D1.  
The isobutyl group mimicking Leu6, in all the compounds, retained some of the binding 
affinity and the various alkoxy groups mimicking Phe8 had a significant effect on the 
activity of each FLIP on CDK2/cyclin A.  SCCP 5977 contains an isobutyl group to 
mimic the Phe8 position in the primary pocket.  This compound had an IC50 value of 
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148.4 μM against CDK2/cyclin A.  SCCP 5979 has a propyl group reaching in to the 
pocket in replacement of Phe8 and has an IC50 value of 181.2 μM against CDK2/cyclin 
A.  Lastly, SCCP 5983 contains an ethyl group which was shown to be slightly less 
potent against CDK2/cyclin A with an IC50 value of 164.02 μM.  All other compounds 
(SCCP 5978, 5980-5982, 5984, and 5985) are not active against either CDK2/cyclin A or 
CDK4/cyclin D1. 
TABLE 2.5. SUMMARY OF THE LEU-PHE MIMETICS  
 
 
 
 
SCCP ID n R1 R2 R3 
CDK2/Cyclin A 
IC50 (µM) 
CDK2/Cyclin A 
IC050 (µM) 
5977 0 iBut iBut H 148.4 >180 
5978 0 iBut iBut H >180 >180 
5979 0 Pr iBut H 181.2 >180 
5980 0 Pr iBut H >180 >180 
5981 1 Me iBut Me >180 >180 
5982 1 Me iBut H >180 >180 
5983 0 Et iBut H 164.02 >180 
5984 0 Et iBut H >180 >180 
5985 0 Me iBut H >180 >180 
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2.3.2 DISCUSSION 
The computationally designed Ccaps, based on commercially available compounds with 
appropriate functionality to mimic both Leu6 and Phe8 of HAKRRLIF, have been 
coupled to the 35DCPT-Arg.  The binding affinity of these novel Ccaps have been 
measured via the FP assay to determine the ability of the FLIP compounds to compete 
with a peptidic inhibitor (tracer peptide) against CDK2/cyclin A and CDK4/cyclin D1.  
Compounds SCCP 5977, 5979, and 5983 (Figure 2.11) are the only FLIPs out of this 
series to show activity against CDK2/cyclin A.  No FLIPs were active against 
CDK4/cyclin D1.   
The isobutyl group replacement for Phe8 (SCCP 5977) appears to be the best alkyl 
group compared to the propyl group (SCCP5979) and the ethyl group (SCCP 5983).  The 
additional methyl group of the isobutyl seems to be a contributor to the retention of 
potency compared to the propyl group.  SCCP 5977 showed an IC50 value of 148.4 μM, 
SCCP 5979 with 181.2 μM and SCCP 5983 with 164.02 μM against CDK2/cyclin A.  
The isobutyl side chain (SCCP 5977) proves to be most potent against CDK2/cyclin A. 
 
We can compare these results to a previously reported FLIP (SCCP 5923; Table 
1.3) that contains 4CPT-Arg5-Leu6 and the 4-(4-fluorophenoxy)pyridin-2-
FIGURE 2.11.  CHEMICAL STRUCTURES OF SCCP 5977, 5979, AND 5983.  Listed are the chemical 
structures for the Ccaps of SCCP 5977, 5979, and 5983.  SCCP 5977 showed an IC
50
 value of 148.4 μM, 
SCCP 5979 has an IC
50
 value of 181.2 μM, and SCCP 5983 with an IC
50
 value of 164.02 μM all against 
CDK2/cyclin A.  These compounds are not active against CDK4/cyclin D1.  The R group for each of these 
compounds is 35DCPT-Arg. 
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yl)methanamine Ccap.  This FLIP compound has an IC50 value of 18.1±4.0 μM.  Section 
1.5 introduced both 35DCPT and 4CPT as Ncaps and when coupled to RLIF (5773 and 
5774, respectively) showed IC50 values of 4.0±0.6 μM and 11.5±3.3 μM, respectively.  
There is a slight difference in the expected binding affinities between SCCP 5979 and 
SCCP 5923 due to the different Ncaps but even with these differences SCCP 5923 is still 
significantly more potent against CDK2/cyclin A.   
2.3.3 MATERIAL AND METHODS 
The computationally designed Ccaps have been coupled to 35DCPT-Arg and their 
binding affinities have been evaluated in a competitive binding assay.  The peptide 
synthesis in which these small molecules were synthesized is illustrated in Scheme 2.3.  
In a round bottom, an arginine (1.32 mmol; 1EQ; 3.935 g) (protected by Pbf and coupled 
to a 2-Chlorotrityl resin) was coupled to 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-
triazole-3-carboxamide (35DCPT; 2EQ; 2.64 mmol; 0.718 g) in the presence of a 
coupling agent (HBTU, 5.808 mmol; 4.4EQ; 2.202 g) and a base (DIPEA, 7.92  mmol; 
6EQ; 1.023 g) in DMF.  The reaction was left to stirr overnight and when HPLC 
confirmed the consumption of starting materials the resin was filtered and washed 
thoroughly with DMF.  The resin was then cleaved with 3-5 percent TFA in DCM for 3 
minutes.  The resin was then filtered and washed several times with DCM until the resin 
returned to a yellow color.  The filtrate was collected and the organic layer was removed 
under reduced pressure yielding 581.26 mg (64.7%).   
The Leu-Phe mimetic Ccaps were then coupled.  In brief, 1-(2-isobutoxyphenyl)-3-
methylbutan-1-amine (0.07346 mmol; 1EQ; 17.29 mg) was coupled to 35DCPT-
Arg(Pbf) (0.07346 mmol; 1EQ; 50 mg) in the presence of HBTU (0.1469 mmol; 2.2EQ; 
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55.72 mg) and DIPEA (0.2938 mmol; 4EQ; 37.971 mg) in DCM.  The reaction was left 
overnight and when HPLC confirmed the consumption of starting materials the reaction 
mixture was concentrated and partitioned between EtOAc and water.  The aqueous layer 
was back extracted with EtOAc.  The organic layers were combined and washed with 1N 
NaOH, 1N HCl, and brine, dried over sodium sulfate, filtered concentrated, and dried 
under vacuum.  Lastly, the side chain of the Arg was deprotected using 95:2.5:2.5 
TFA:water:TIPS overnight.  Once deprotection was confirmed the solvents were 
removed under reduced pressure.  Due to this compound having a chiral center, 
diastereomers were synthesized and were separated by prep-HPLC resulting in 0.940 mg 
(0.02%; SCCP 5977) and 1.180 mg (0.025%; SCCP 5978).  MS (EI+) 645. The FP assay 
was used to measure the binding affinity of these novel Ccaps.  In this assay, each FLIP 
compound was tested against CDK2/cyclin A and CDK4/cyclin D1.   
.
SCHEME 2.3.  GENERAL REACTION SCHEME FOR THE SYNTHESIS OF THE LEU-PHE MIMETICS.  As seen 
in this scheme, the arginine linker attached to a resin was coupling with the desired Ncap of 35DCPT.  This 
product was then cleaved from the resin and coupled with the novel Leu-Phe mimetic Ccaps.   
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CHAPTER 3 
DEVELOPMENT OF FRAGMENT LIGAND INHIBITORY PEPTIDES CONTAINING 
NON-NATURAL AMINO ACIDS
 
In the effort to convert HAKRRLIF into a more drug-like molecule by the REPLACE 
strategy, the C-terminal amino acids (RLIF) need to be replaced by small molecules for 
the complete conversion of the octamer into a cell permeable, non-peptidic inhibitor.  
Chapter 2 describes a valid approach in the replacement of LIF of the octamer.  Chapter 3 
introduces the replacement of the critical arginine amino acid by an alternative approach.  
The replacement of Arg5 has been attempted by the inclusion of non-natural arginine 
derivatives.  These isosteres have been utilized to explore their effects on the binding 
affinity of the FLIP molecules, further establish SAR for this interaction, and potentially 
improve drug-likeness through enhancing stability and cell permeability.  
3.1 ARGININE ISOSTERES 
Isosteric arginine derivatives have been utilized as linkers between 35DCPT and a C-
terminal dipeptide, β-Leu-NMethylPhe-NH2.  These non-natural amino acids form amide 
bonds similarly to natural amino acids but have side chains that distinguish them
43
.  The 
non-natural amino acids have been synthesized and incorporated into the FLIP 
compounds to enhance pharmacokinetics and the inhibitory activities of peptides
37a
.  The 
library of non-natural arginine derivatives obtained may (1) potentially mimic the 
interactions that are made between the CBM (Arg5) and the CBG (Asp283), (2) evaluate 
the steric requirements of this position, (3) improve drug-like properties, and (4) most 
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likely improve the binding affinity of the FLIPs through favoring increased ion-pairing 
interactions.  Currently, structure-activity relationship (SAR) data for this interaction is at 
the initial stages.  The replacement of Arg5 with various amino acids has been done with 
activity still present however at a decreased amount of 4-fold or greater.  The arginine at 
this position is important for the binding affinity of HAKRRLIF and therefore varying 
the functionality of these arginine derivative side chains will aid in the further 
development of the SAR and possibly the replacement for this position.   
3.2 RESULTS AND DISCUSSION 
The arginine isosteres listed in Table 3.1 were Fmoc-protected prior to solid phase 
synthesis with the dipeptide Ccap, β-Leu-NMethylPhe-NH2.  These FLIPs were then 
Ncapped with 35DCPT.  The alkylation of the guanidine group in these isosteres provide 
functionality and should protect the guanidine groups from reacting during peptide 
synthesis.  These side chains are expected to interact with Asp283 of the CBG and help 
establish further SAR.   
Peptides composed of naturally occurring amino acids are useful as lead 
compounds in discovering new drug therapies but generally speaking are limited as 
therapeutics by their undesirable pharmacokinetic profiles.  These are caused by their 
poor permeability (blood brain barrier, cell membrane, etc.) and lack of metabolic 
stability including protease-mediated degradation
37
.  While naturally occurring amino 
acids are not ideal for novel drug therapies, their non-natural counterparts allow 
modification to improve drug-likeness.  Appropriate non-natural amino acids, such as 
these arginine isosteres, can be incorporated into compounds in order to increase 
lipophilicity and potentially improve the pharmacokinetic parameters, the 
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agonist/antagonist behaviors, and may promote ion-pairing
37a
.  This ion-pairing 
interaction is enhanced by incorporating alkyl groups on the side chains of guanidine 
containing residues.  The alkyl groups destabilize solvation of the charged side chain 
promoting ion-pairing and the binding to the target
44
. 
TABLE 3.1. SUMMARY OF THE ARGININE ISOSTERES 
 
  
R 
 
 
 
 The incorporation of non-natural amino acids can allow compounds to evade 
peptidase digestion thus creating a more stable compound
44
.  Having a more stable 
compound should result in an increased half-life of the compound in the circulatory 
system of patients
44
.  This improved stability can potentially be achieved through 
modifications to the side chains of amino acids and may include, but are not limited to, 
the incorporation of halogens, unsaturated hydrocarbons, heterocycles, silicon, and 
organometallic units
45
.  By adding appropriate non-natural amino acids in the non-
peptidic inhibitor, functionality can be incorporated to help enhance pharmacokinetic 
parameters, enhance the inhibitory abilities of peptides and promote favorable ion-pairing 
37a, b
.  Varying the side chains can also provide SAR data to further optimize the 
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functionality of these side chains.  
Non-natural arginine derivatives, gifted to the McInnes lab from the Dix laboratory 
at the Medical University of South Carolina, have been utilized to replace Arg5 of the C-
terminal pentapeptide (RRLIF; Table 3.1).  The side chains of these arginine derivatives 
contain functional groups such as acyclic (methyl and ethyl) and cyclic (4,5-dihydro-1H-
imidazole and 1,4,5,6-tetrahydropyrimidine) groups.  These groups may provide 
protection to the guanidine group to elude reactivity during peptide synthesis.  These 
modified guanidines will help establish further SAR data for the interactions between the 
Arg5 of the CBM and Asp283 of the CGB.   
The arginine derivatives have been Fmoc-protected prior to solid phase peptide 
synthesis with a C-terminal dipeptide, β-Leu-NMethylPhe-NH2 and Ncapped with 
35DCPT.  The C-terminal dipeptide has been previously tested in the FP assay as RR(β-
Leu)NMePhe-NH2 (SCCP 5941) and is a potent inhibitor of CDK2/cyclin A with an IC50 
value of 0.405±0.091 µM.  To incorporate this C-terminal dipeptide with the current 
isosteres, the natural arginine was been replaced with an arginine derivative.  The identity 
of the Arg isostere-dipeptide was confirmed by Liquid Chromatography-Mass 
Spectrometry (LCMS), was Ncapped with 35DCPT and the final FLIP compound was 
cleaved from the resin but the M+S did not confirm the desired product but indicates that, 
in this case, the guanidine group was able to react readily with the activated 35DCPT and 
resulted in double Ncapped FLIP compounds (Appendix C).  During purification two 
peaks were isolated and identified through MS.  The first isolated peak has an m/z of 
1010 (Appendix C; C1) which theoretically corresponds to the addition of 35DCPT 
twice.  It is believed that the additional Ncap is coupled to the guanidine side chain; 
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further analysis will confirm the exact structure that relates to this mass.  The other 
fraction that was isolated has an m/z of 559 (data not shown).  This mass corresponds to 
35DCPT-βL-NMethylF indicating that the addition of the arginine isosteres was not 
complete.   
To address this issue several different parameters will be varied to elude such 
outcomes.  During the initial synthesis 35DCPT was used in excess and the reaction 
occurred overnight.  To resolve the current issue, the Ncap and Arg isosteres-dipeptide 
will be used at the same scale (1:1 ratio) and the reaction will be monitored closely 
through HPLC until the starting materials are consumed.  If the guanidine still proves to 
be readily reactive, protection of this group will be employed.  Common protecting 
groups for guanidines are 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) and 
2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc).  The addition of the sulfonamide group 
masks the reactivity of the guanidine and these groups are easily removed with high 
concentrations of acid.   
3.3 MATERIALS AND METHODS 
Following the synthesis of the arginine derivatives, the amine group on the alpha carbon 
was protected by 9-Fluorenylmethyl N-succinimidyl carbonate (Fmoc-O Suc) via Fmoc 
protection in aqueous solution.  For example, N-methyl arginine (1.328 mmol; 1EQ; 250 
mg) was combined with Fmoc-O Suc (1.859 mmol; 1.4EQ; 627.10 mg) in a 3:1 ratio of 
water and ethanol
46
.  The reaction mixture was stirred for 4 to 6 hours at 60 degrees 
Celsius.  Once complete, the reaction mixture was cooled to zero degrees Celsius, 
acidified to pH 4-5, and extracted with EtOAc
46
.  The aqueous layer was evaporated 
under reduced pressure and purified by FLASH chromatography. 
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The Fmoc-N-methyl arginine was then coupled to 35DCPT and a C-terminal 
dipeptide sequence of β-Leu-NMethylPhe-NH2 via solid phase peptide synthesis (Scheme 
3.1).  In brief, Fmoc protected Rink Amide Resin (0.75 mmol; 1EQ; 1.19 g) was pre-
swelled in DMF for 30 minutes.  The resin was then placed into a solid phase peptide 
synthesis vessel, and the Fmoc group protecting the resin was deprotected with 20% 
piperidine in DMF for 30 minutes
47
.  The resin was then filtered and rinsed thoroughly 
with DMF.  Fmoc-N-MethylPhe (1.5 mmol; 2EQ; 0.6022 g) was then coupled using dry 
DMF, HBTU as the coupling agent (3.375 mmol; 4.4EQ; 1.280 g), and DIPEA as base 
(4.5 mmol; 6EQ; 0.5816 g) with nitrogen was bubbled into the vessel for stirring.  After 4 
to 6 hours a ninhydrin test confirmed consumption of the starting material and the resin 
was filtered and rinsed several times with DMF and the Fmoc group was deprotected 
using 20% piperidine in DMF under nitrogen.  Next, the Fmoc-β-Leu (1.5 mmol; 2EQ; 
0.5512 g) was coupled in the same manner and the Fmoc protecting group was 
deprotected.   
The Fmoc-N-methyl arginine (0.561 mmol; 5EQ; 0.230 g) was coupled to the 
dipeptide-resin (0.112 mmol; 1EQ; 0.277 g) for 24 to 36 hours in the presence of HBTU 
(1.008 mmol; 11EQ; 382.27 mg), DIPEA (1.380 mmol; 15EQ; 178.35 mg), DNF and 
nitrogen was bubbled into the vessel for stirring.  When the ninhydrin test confirmed the 
consumption of the starting materials, the resin was then filtered and washed thoroughly 
with DMF.  The Ncap, 35DCPT, (0.240 mmol; 2EQ; 0.0653 g) was then attached by the 
same procedure for 12 hours.  To complete the synthesis, the rink amide resin was 
removed from the vessel, placed into a round bottom and was cleaved using 20% TFA in 
DCM for 20 minutes and rinsed several times with DCM.  Following resin cleavage, the 
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filtrate was collected and the organic solvent was removed under reduced pressure.  The 
product was purified by prep-HPLC and tested in the FP assay for their binding. 
 
 
SCHEME 3.1.  GENERAL REACTION SCHEME FOR THE PEPTIDE SYNTHESIS OF THE ARGININE ISOSTERS.  
An amide rink resin was deprotected and coupled with the coupled with NMethyl-Phe and β-Leu.  This 
dipeptide was then coupled with an arginine isosteres and Ncapped with 35DCPT.  These peptides were 
synthesized via solid phase peptide synthesis. 
 61 
CHAPTER 4 
ALTERNATIVE APPROACHES AND THE FUTURE  
DIRECTION OF CDK INHIBITORS
 
SECTION 4.1 ALTERNATIVE APPROACHES 
Another strategy for the development of CDK inhibitors for use in oncology beyond 
targeting the ATP binding pocket and the cyclin binding groove is to inhibit the 
formation of the CDK/cyclin complex.  Such inhibitors interfere with the protein-protein 
interface between CDK2 and cyclin A.  Cyclin A binds to CDK2 by interacting with the 
N- and C-terminal lobes through PPI
48.  When the α3 and α5 helices of cyclin A bind to 
the PSTAIRE helix of CDK2 major conformational rearrangements occur resulting in an 
inactive intermediate complex
48
.  This process is the initial step in the CDK/cyclin 
complex formation followed by a gradual conformational reorganization to expose the T 
loop of CDK2.  The T-loop is then phosphorylated by the cyclin activating kinase (CAK) 
to form the substrate binding site
48.  A peptide was developed, C1, based on the α5 
helices of the cyclin, to target this interface and has shown to inhibit CDK2/cyclin A 
activity towards histone H1 and pRb fused with GST
48
.  A derivative of this peptide, C4, 
containing a point mutation to increase solubility, was shown to inhibit CDK2 kinase 
activity when associating with either cyclin A or cyclin E
48
.  Figure 4.1 illustrates the 
binding placement for C4 on the cyclin subunit.  However, CDK1/cyclin B, protein 
kinase A and protein kinase C were not affected by C4
48.  C4 was shown to adopt an α-
helical conformation that mimics the hydrophobic interactions between CDK2 and cyclin 
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A and this is understood as to how the inhibition of this complex occurs
48
.  C4 promotes a 
conformational change that induces the CDK2/cyclin A complex into an inactive 
conformation and was shown to not bind to pre-existing CDK2/cyclin A complexes or 
free CDK2
48
.  Concluding that C4 is potentially a selective inhibitor of CDK2/cyclin A 
and this was validated when tested in estrogen-independent MDA-MB-231 breast cancer 
cells
48
.  C4 was able to completely inhibit cellular proliferation
48
.   
 
 A second compound, NBI1, has also been identified as a CDK2/cyclin A inhibitor 
that targets neither the ATP binding pocket nor the CBG
48
.  NBI1 is a hexapeptide that 
contains all D-amino acids and is known to only interact with the cyclin subunit by 
binding to the region containing the α3, α4, and α5 helices, illustrated in Figure 4.148-49.  
NBI1 showed an IC50 value against CDK2/cyclin A of 1.1 µM
49
 and it is believed that 
NBI1 affects the stability of the CDK/cyclin complex
48
.  Inhibition of CDK2/cyclin A 
results in elevated E2F-1 activity leading to cell cycle arrest in S phase resulting in 
apoptosis
49
.  Unlike C4, NBI1 was shown to inhibit CDK1/cyclin B and CDK6/cyclin D3 
FIGURE 4.1.  ILLUSTRATION OF A CDK/CYCLIN COMPLEX.  A. The ATP binding site is located on the 
CDK and the cyclin binding groove on the cyclin.  C4 and NBI1 bind to the interface between CDK2 and 
cyclin A.  [Reprinted with permission from Orzaez, M., A. Gortat, et al. (2009). "ATP-noncompetitive 
inhibitors of CDK-cyclin complexes." ChemMedChem 4(1): 19-24. ] B. The three major sites discussed in 
this section are illustrated; α5 helix, PSTAIRE, and the T-loop all located on the interface between CDK2 
and cyclin A. [Gondeau, C., S. Gerbal-Chaloin, et al. (2005). "Design of a novel class of peptide inhibitors 
of cyclin-dependent kinase/cyclin activation." The Journal of biological chemistry 280(14): 13793-13800.] 
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but did not show inhibition against a panel of other serine/threonine protein kinases
48
.  A 
derivative of NBI1, TAT-NBI1 (TAT is a cell penetrating carrier), was tested against 
numerous cell lines at various concentrations and CDK1 and CDK2 activities were 
significantly decreased whereas CDK4 was only minimally inhibited and demonstrated to 
have cells arrest in the S or G2/M phases
48
.  TAT-NBI1 in a concentration and time 
dependent manner inhibited cell proliferation by inducing S phase arrest and apoptosis in 
glioblastoma, colon, and ovarian cancer cells
49
. 
 NB11 has been proven to be a selective inhibitor of the association between 
CDK2/cyclin A with remarkable affinity however, this small molecule is a weak inhibitor 
of CDK2/cyclin E
49
.  Both cyclins associate with the same CDK therefore the different 
selectivity between the two complexes must be due to structural differences amongst the 
cyclins
49
.  This suggests that the development for an alternative inhibitor for the 
inhibition of CDK2/cyclin E is necessary.  A potential advantage of targeting the CBG is 
the inhibition of all the cell cycle CDKs due to the conserved sequence recognition 
(CBM) across cyclins A, E and D-type.   
SECTION 4.2 FUTURE DIRECTIONS 
The REPLACE methodology has successfully aided in the identification of novel Ccaps.  
The most potent FLIP compound reported here is SCCP 6004 with an IC50 value of 57.74 
µM against CDK2/cyclin A. The Ccap of this FLIP and many other potential Ccaps were 
identified by the AnchorQuery™ software.  The fragments chosen for the work in this 
thesis closely mimic the position of Leu6 and Phe8 in the primary hydrophobic pocket.  
The software also returned a similar small molecule to 2-amino-N-ethyl-4-methyl-N-(3-
phenylpropyl)pentanamide (Ccap of SCCP 6005 and 6014; Figure 2.7).  This fragment 3-
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amino-N-phenethyl-3-phenyl-N-(2,2,2-trifluoroethyl)propanamide (Figure 4.2) and is of 
interest to further build the SAR.  The trifluoroethyl group of this small molecule could 
be replaced with a small alkyl group because it does not make intermolecular interactions 
within the pocket, although having a group at this position may be important 
geometrically.  The aromatic ring positioned in the Leu6 position is expected to have a 
binding mode similarly to Leu6 and be space-filling.   
 
 Based on the results from the Ccaps tested in Chapter 2, a series of Ccaps have 
been designed that are of interest (Table 4.1).  These Ccaps (Table 4.1) will be 
synthesized and undergo solid phase synthesis similarly to that which is illustrated in 
Scheme 2.1.  The Ccaps (No. 1-4) differ from SCCP 6000 – 6005 and 6014 (Table 2.3) 
by the group in the Leu6 position which is either leucine or β-leucine.  The new Ccaps 
will contain phenylalanine, histidine, β-phenylalanine, or β-histidine depending on the 
length of the alkyl chain at the n2 position seen in Table 2.3.  These derivatives will help 
further establish the SAR for the Leu6 position.  The variation of the ring size plus the 
addition of potential ion-pairing interaction of the imidazole ring of histidine will aid in 
FIGURE 4.2.  POTENTIAL FRAGMENT SUPERIMPOSED WITH HAKRRLIF IN THE PRIMARY 
HYDROPHOBIC POCKET.  3-amino-N-phenethyl-3-phenyl-N-(2,2,2-trifluoroethyl)propanamide 
superimposed with HAKRRLIF in the primary hydrophobic pocket.  This small molecule closely mimics 
the pose of LEU6 and PHE8 and therefore is a potential Ccap of interest.   
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the determination of which functional group(s) would best retain or enhance the binding 
affinity of this position.  Leu6 has previously been determined to be the most critical 
amino acid of the octamer (HAKRRLIF) and therefore its replacement has been 
challenging but has also been shown that this position is capable of being replaced with a 
small molecule.   
SCCP 6004 has shown to be the most potent FLIP of the compounds reported here.  
SCCP 6004 has been structurally modified (Table 4.1; No. 5-8) to help regain activity 
that was lost due to fragment replacement.  These modified FLIP compounds will contain 
the addition of halogens on the aromatic ring at either the 4-position or the 3,5-position.  
Previously, a library of bis(aryl) ether Ccaps were generated.  The first of this series was 
a FLIP compound contained 4CPT-RL-(3-phenoxyphenyl)methanamine (SCCP 5807) 
showed an IC50 value of 106.1±26.2 µM against CDK2/cyclin A.  Following the addition 
of halogens on the aromatic ring the binding affinities for these compounds increased 2-5 
fold compared to SCCP 5807.  SCCP 5824 and 5823 (Table 1.3) contain fluoro groups at 
the 3 and 4 position with IC50 values of 53.2±11.6 µM and 18.1±4.0 µM against 
CDK2/cyclin A, respectively.   
Of Table 4.1, compounds No. 5 and 7 contain a chlorine and fluorine at the 3 and 5 
positions, respectively.  Modeling these compounds using Discovery Studio showed that 
the addition of halogens to these fragments does not clash with the protein and therefore 
may potentially enhance the current activity of SCCP 6004. Compounds No. 6 and 8 have 
either a chlorine or fluorine at the 4 position of the aromatic ring, respectively.  Having a 
chlorine at this position severely clashed with the protein when structurally designed in 
Discovery Studio and thus a compound containing this functional group may result in a 
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loss of activity that SCCP 6004 currently has.  The fluorine at the 4 position however has 
a good complementarity with the binding pocket.  Such compounds will be tested in the 
competitive binding assay to determine the effects of halogenation.   
TABLE 4.1.  SUMMARY OF C-TERMINAL CAPPING GROUPS OF INTEREST.  
 
 
No. n1 n2 R1 R3 R4 R5 
1 0 3  
H H H 
2 1 3 
H H H 
3 0 3  
H H H 
4 1 3 
H H H 
5 0 3 
 
Cl H Cl 
6 0 3 
H Cl H 
7 0 3 
F H F 
8 0 3 
H F H 
 
SECTION 4.3 PREDICTION OF CELLULAR ACTIVITY OF NOVEL CCAPPED FLIPS 
The work reported here has identified a series of FLIP compounds that further validate 
the REPLACE methodology through the replacement of the C-terminal amino acids with 
fragments that have IC50 values comparable to those previously reported.  With further 
modification these Ccaps have the potential to be 2-fold or more potent than the bis(aryl) 
ether Ccaps which has an IC50 value of 18.1±4.0 µM against CDK2/cyclin A.  The next 
major step in this project is to generate cell permeable compounds.   
 67 
 Mendoza et al. (2003) reported that RXL peptides have the ability to block the 
recruitment of E2F-1 and its phosphorylation through the inhibition of CDK2/cyclin A as 
well as selectively promote apoptosis in cells with deregulated CDK4/6-cyclin D-INK4-
pRb pathway
50
.  The peptides PVKRRLDL and PVKRRLFL were coupled to fusion 
peptides (penetratin) to promote entry into cells
50
.  During standard cell viability assays 
both PEN-PVKRRLDL and PEN-PVKRRLFG peptide inhibited the proliferation of an 
osteosarcoma (U2OS) cell line in a concentration-dependent manner
50
.   
Cell proliferation assays were conducted in house with HeLa (p53 defective), 
prostate cancer Du145 (pRb null), and osteosarcoma U2OS (p16 defective which should 
upregulate E2F-1 activity) cell lines.  Peptides containing the fusion peptide or peptide 
alone showed that both a peptide alone (SCCP 5995; SAKRR-βL-3TA-G) and a 
scrambled fusion peptide (SCCP 5991; PEN-ETDHQYLAESS) have no effect on growth 
inhibition, both with IC50 values greater than 100 µM (Table 4.2).  A weakly binding 
control (SCCP 5990; PEN-PVKRRAFG) shows growth inhibition against all three cell 
lines with IC50 values of 49.9±0.6 μM (HeLa), 24.9±1.9 µM (Du145) and 42.5±1.9 μM 
(U2OS).  A positive control (SCCP 5994; PEN-SAKRR-βL-3TA-Gly) has growth 
inhibition in only Du145 (38.5±4.3 µM) and U2OS (43.1±1.1 μM) cell lines.  SCCP 5989 
a fusion peptide used by Mendoza et al. (2003) with the peptide sequence of PEN-
PVRRLFG showed to have an IC50 values of approximately 30 µM in all three cell lines.   
Efforts are also being made to put FLIP compounds with well-established 
competitive binding assay IC50 values into cancer cell lines.  Prostate (DU145) and 
osteosarcoma (U2OS) cell lines have been treated with SCCP 5963 and 5964 (Table 4.3).  
These FLIPs showed IC50 values of 6.49±0.27 µM and 7.91±5.08 µM against 
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CDK2/cyclin A, respectively.  When DU145 prostate cells were treated with SCCP 5963 
and 5964 the IC50 values obtained were 36.5±2.6 µM and 21.8±0.32 µM, respectively.  
The U2OS osteosarcoma cells had similar results with IC50 values of 30.7±2.7 µM for 
SCCP 5963 and 18.3±1.5 µM for SCCP 5964.  SCCP 5963 has comparable growth 
inhibition compared to SCCP 5989 however, SCCP 5964 has a greater growth inhibition 
than SCCP 5989.   
TABLE 4.2. SUMMARY OF VARIOUS PEPTIDE ACTIVITIES IN CELL LINES. 
 
To aid in the prediction of cell permeability, ADMET (absorption, distribution, 
metabolism, excretion, and toxicity) parameters have been calculated for SCCP 5963, 
5964, and 6004 as well as the new FLIP compounds of interest for the future (Table 4.4).  
ADMET parameters such as solubility between 0-1, absorption between 3-4, Lipinski’s 
Rule of 5 (molecular weight (MW) <500, logP <5, the number of hydrogen bond donors 
(HBD) <5, and the number of hydrogen bond acceptors (HBA) <10), the number of 
rotatable bonds (≤10), and the polar surface area (PSA) (≤140) are ideal for cell 
permeability.  SCCP 5964 (Table 4.4) was the most active in the cell proliferation assay 
and when compared to SCCP 5963, it has a more ideal solubility level, lowest logP value, 
fewer HBA and fewer rotatable bonds but has the highest PSA.   
The most active compound from the novel Ccaps reported here is SCCP 6004.  
This FLIP has comparable solubility and absorption levels and has fewer HBD, HBA, 
SCCP 
HeLa 
IC50 (μM) 
Du145 
IC50 (μM) 
U2OS 
IC50 (μM) 
5990 49.9±0.6 24.9±1.9 42.5±1.9 
5995 >100   
5989 30.3±1.4 32.3±3.2 28.9±2.2 
5991 >100 >100 >100 
5994 >100 38.5±4.3 43.1±1.1 
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and rotatable bonds to SCCP 5964.  The logP value for SCCP 6004 is significantly higher 
than that of SCCP 5964 and has almost 1.5 fold less PSA.  This may conclude that SCCP 
6004 will be more cell permeability compared to SCCP 5964.  With these ADMET 
values it can be predicted that SCCP 6004 will have greater cell permeability but may 
have slightly less activity based on its binding affinity in the FP assay.  
TABLE 4.3. SUMMARY OF FLIP ACTIVITY IN COMPETITIVE BINDING AND CELL PROLIFERATION 
ASSAYS 
 
     
   Competitive Binding Assay Cell proliferation Assay 
SCCP R1 R2 
CDK2/Cyclins A 
IC50 (µM) 
CDK4/Cyclins D1 
IC50 (µM) 
DU145 
IC50 (µM) 
U2OS 
IC50 (µM) 
5963 Me 
 
6.49±0.27 >100 36.5±2.6 30.7±2.7 
5964 H  7.91±5.08 >100 21.8±0.32 18.3±1.5 
 
The FLIP compounds of interest for the future also have comparable solubility and 
absorption levels (Table 4.4).  Compounds No. 3 and 4 have comparable logP values and 
lower PSA values than SCCP 5964 which may indicate a slight increased in cell 
permeability.  All other FLIPs have greater logP values, similar number of HBD, HBA 
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and rotatable bonds, and lower PSA values.  This may contend that these FLIPs may have 
cell permeability and activity but will most likely not be greater than that of SCCP 5964.  
Compound No. 6 has the highest logP value (without exceeding the limit of 5) and one of 
the lowest PSAs, therefore this FLIP can be predicted to be the most cell permeable of 
Table 4.4). 
TABLE 4.4. ADMET RESULTS FOR CURRENT AND FUTURE FLIPS. 
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1 706.279 2 3 4.510 8 12 18 181.65 
2 692.263 2 3 4.054 8 12 17 181.65 
3 682.254 2 3 2.398 9 14 17 210.33 
4 696.64 2 3 2.083 9 14 17 210.33 
5 726.201 1 3 5.373 8 12 17 181.65 
6 692.240 1 3 4.708 8 12 17 181.65 
7 694.260 1 3 4.455 8 12 17 181.65 
8 676.269 2 3 4.250 8 12 17 181.65 
 
As for the arginine isosteres, changing the functionality at this position affects 
mainly logP and PSA (Table 4.5).  The solubility and absorption levels remain consistent 
with the altered side chains and the number of HBD, HBA, and rotatable bonds are 
comparable across the table.  However, the PSA values decrease by 13 to 25 units and the 
logP values increase with added functionality.  With the increase in logP and the decrease 
 71 
in PSA, these arginine isosteres are expected to be promising replacements for natural 
arginine.  Theoretically, if arginine isosteres 2 or 3 were introduced into a compound like 
SCCP 5964 the cell permeability and potentially the activity would increase due to the 
effects of the altered side chain.   
TABLE 4.5. RESULTS FOR ARGININE ISOSTERES. 
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Natural Arg 
116.12 5 0 0.308 5 3 4 63.64 
1 
130.13 5 0 0.514 4 3 5 49.65 
2 
144.15 4 0 0.720 3 3 5 38.03 
3 
144.15 5 0 0.863 4 3 6 49.65 
4 
142.13 4 0 0.538 3 3 4 38.03 
5 
156.15 4 0 0.601 3 3 4 38.03 
 
SECTION 4.4 CONCLUSIONS 
There are frequent deregulations of endogenous CDKIs in human cancers and the 
development of novel CDK inhibitors is being investigated by targeting the CBG.  
Currently, non-peptidic inhibitors are being developed based on the HAKRRLIF which is 
derived from the C-terminal peptide sequence of the CDK inhibitor p21
WAF1
.  Reported 
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here, computational design (structure- and pharmacophore-based) and the incorporation 
of arginine isosteres have been utilized to identify PLAs to replace the C-terminal amino 
acids (RLIF) by the REPLACE methodology.  These FLIPs have been synthesized, 
coupled with a potent Ncap, and their binding affinities have been tested using an FP 
assay.  Of the FLIP compounds generated, SCCP 6004 was determined to have the 
greatest potency against CDK2/cyclin A with and IC50 value of 57.74 µM.  Furthermore, 
ADMET values have been calculated for SCCP 6004 for the comparison with a known 
cell permeable FLIP, SCCP 5964.  SCCP 6004 may have comparable or greater cell 
permeability than SCCP 5964 however further optimization of SCCP 6004 is needed for 
this compound to be more active in cells.  ADMET values were also calculated to 
compare natural arginine with the arginine isosteres listed here.  Isostere number 2 is 
expected to have the greatest impact on cell permeability and cellular activity if it were to 
be incorporated into a compound similar to SCCP 5964.   
The results reported here have enhanced the development of a selective, drug-like, 
cell permeable CDK inhibitors by generating promising Ccaps and by identifying a novel 
approach for the design of PLAs.  Furthermore, these results bring this project closer to 
achieving the ultimate goal of developing a novel class of cancer therapeutics based on 
cell cycle inhibition.   
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APPENDIX A 
ANCHORQUERY™ IDENTIFIED CCAP CHARACTERIZATION 
 
SCCP 6000 
 
A1.  MS results for N-((2S)-1-((1-(benzylamino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-1-
oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6000). MS(ES): 
m/z: 644 [M+H]
+
 (100%) 
 
 
A2.  HPLC trace of N-((2S)-1-((1-(benzylamino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-1-
oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6000). 
 
 81 
SCCP 6001 
 
A3.  MS results for N-((2S)-1-((1-(benzyl(ethyl)amino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-1-
oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6001). MS(ES): 
m/z: 672 [M+H]
+
 (100%) 
 
 
A4.  HPLC results for N-((2S)-1-((1-(benzyl(ethyl)amino)-5-methyl-1-oxohexan-3-yl)amino)-5-guanidino-
1-oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6001).  
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SCCP 6002 
 
A5.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((5-methyl-1-oxo-1-
(phenethylamino)hexan-3-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6002). MS(ES): m/z: 658 [M+H]
+
 (100%) 
 
 
A6.  HPLC results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((5-methyl-1-oxo-1-
(phenethylamino)hexan-3-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6002). MS(ES):  
 83 
SCCP 6003 
 
A7.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(phenethyl)amino)-5-methyl-1-oxohexan-3-
yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 6003). 
MS(ES): m/z: 686 [M+H]
+
 (100%) 
 
 
A8.  HPLC results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(phenethyl)amino)-5-methyl-1-
oxohexan-3-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6003).  
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SCCP 6004 
 
A9.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((4-methyl-1-oxo-1-((3-
phenylpropyl)amino)pentan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide 
(SCCP 6004). MS(ES): m/z: 658 [M+H]
+
 (100%) 
 
 
A10.  HPLC results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((4-methyl-1-oxo-1-((3-
phenylpropyl)amino)pentan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide 
(SCCP 6004).  
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SCCP 6005 
 
A11.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6005). MS(ES): m/z: 686 [M+H]
+
 (100%) 
 
 
A12.  HPLC results for 1 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6005).  
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SCCP 6014 
 
A13.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6014). MS(ES): m/z: 686 [M+H]
+
 (100%) 
 
 
A14.  HPLC results for 1 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(ethyl(3-phenylpropyl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 
6014).  
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A TABLE 1.  
 
SCCP Purity 
Column 
Dimensions Method 
Flow 
Rate 
HPLC 
RT 
Theoretical 
MW 
6000 >92.7% 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 29.37 644.60 
6001 >98.0% 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 31.07 672.65 
6002 >90.0% 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 30.25 658.62 
6003 >98.0% 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 31.47 686.67 
6004 >95.0% 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 30.50 658.62 
6005  4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min   
6014  4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min   
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APPENDIX B 
LEU6/PHE8 MIMETIC CHARACTERIZATION
 
SCCP 5977 and 5978 
 
 
B1.  HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-isobutoxyphenyl)-3-
methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5977 and 5978).   
 
B2.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-isobutoxyphenyl)-3-
methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5977 and 5978).  
MS(ES): m/z: 645 [M+H]
+
 (100%) 
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SCCP 5979 and 5980 
 
 
 
  
 
 
B3.  HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((3-methyl-1-(2-
propoxyphenyl)butyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5979 
and 5980). 
 
B4.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((3-methyl-1-(2-
propoxyphenyl)butyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5979 
and 5980).  MS(ES): m/z: 631 [M+H]
+
 (100%) 
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SCCP 5981 
 
 
 
  
 
 
 
B5.  HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxy-5-methylphenyl)-3-
methylbutan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5981). 
B6.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxy-5-methylphenyl)-3-
methylbutan-2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5981).  
MS(ES): m/z: 617 [M+H]
+
 (100%) 
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SCCP 5982 
 
 
 
  
 
 
B7.  HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3-methylbutan-
2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5982). 
 
B8.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3-methylbutan-
2-yl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5982).  MS(ES): m/z: 
603 [M+H]
+
 (100%) 
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SCCP 5983 and 5984 
 
 
 
  
 
 
B9.  HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(2-ethoxyphenyl)-3-methylbutyl)amino)-5-
guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5983 and 5984).  
B10.  MS results for 1-(3,5-dichlorophenyl)-N-((2S)-1-((1-(2-ethoxyphenyl)-3-methylbutyl)amino)-5-
guanidino-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5983 and 5984).  MS(ES): 
m/z: 617 [M+H]
+
 (100%) 
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SCCP 5985 
 
 
 
 
 
 
B11.  HPLC trace of 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3-
methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5985).  
 
B12. MS results for 1-(3,5-dichlorophenyl)-N-((2S)-5-guanidino-1-((1-(2-methoxyphenyl)-3-
methylbutyl)amino)-1-oxopentan-2-yl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (SCCP 5985).  MS(ES): 
m/z: 603 [M+H]
+
 (90%) 
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B TABLE 1. 
 
SCCP Purity 
Column 
Dimensions Method 
Flow 
Rate 
HPLC 
RT 
Theoretical 
MW 
5977 >79.20 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 46.63 645.62 
5978 >83.50 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 47.42 645.62 
5979 >97.70 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 44.35 631.60 
5980 >96.00 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 45.42 631.60 
5981 >98.00 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 41.18 617.57 
5982 >98.00 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 39.07 603.54 
5983 >82.90 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 41.82 617.57 
5984 >98.00 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 41.72 617.57 
5985 >82.60 4.6 × 250 mm 
5-95% acetonitrile/water/ 
0.1%TFA 
1ml/min 40.62 603.54 
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APPENDIX C 
SCCP 6010 CHARACTERIZATION 
 
 
C1.  HPLC trace of N-((2S)-1-((1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-5-methyl-1-
oxohexan-3-yl)amino)-5-((1-(1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carbonyl)-1,4,5,6-
tetrahydropyrimidin-2-yl)amino)-1-oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carboxamide.  
 
 
C2. MS results for N-((2S)-1-((1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)amino)-5-methyl-1-
oxohexan-3-yl)amino)-5-((1-(1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carbonyl)-1,4,5,6-
tetrahydropyrimidin-2-yl)amino)-1-oxopentan-2-yl)-1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carboxamide.  MS(ES): m/z: 1010 [M+H]
+
 (10-15%) 
 
